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Objectives: To determine whether repetitive
functional task practice (RFTP) after stroke improves
limb-specific or global function or activities of daily
living and whether treatment effects are dependent on
the amount of practice, or the type or timing of the
intervention. Also to provide estimates of the cost-
effectiveness of RFTP.
Data sources: The main electronic databases were
searched from inception to week 4, September 2006.
Searches were also carried out on non-English-language
databases and for unpublished trials up to May 2006. 
Review methods: Standard quantitative methods
were used to conduct the systematic review. The
measures of efficacy of RFTP from the data synthesis
were used to inform an economic model. The model
used a pre-existing data set and tested the potential
impact of RFTP on cost. An incremental cost per
quality-adjusted life-year (QALY) gained for RFTP was
estimated from the model. Sensitivity analyses around
the assumptions made for the model were used to test
the robustness of the estimates.
Results: Thirty-one trials with 34 intervention–control
pairs and 1078 participants were included. Overall, it
was found that some forms of RFTP resulted in
improvement in global function, and in both arm and
lower limb function. Overall standardised mean
difference in data suitable for pooling was 0.38 [95%
confidence interval (CI) 0.09 to 0.68] for global motor
function, 0.24 (95% CI 0.06 to 0.42) for arm function
and 0.28 (95% confidence interval 0.05 to 0.51) for
functional ambulation. Results suggest that training may
be sufficient to have an impact on activities of daily
living. Retention effects of training persist for up to 
6 months, but whether they persist beyond this is
unclear. There was little or no evidence that treatment
effects overall were modified by time since stroke or
dosage of task practice, but results for upper limb
function were modified by type of intervention. The
economic modelling suggested that RFTP was 
cost-effective. Given a threshold for cost-effectiveness
of £20,000 per QALY gained, RFTP is cost-effective 
so long as the net cost per patient is less than £1963.
This result showed some sensitivity to the assumptions
made for the model. The cost-effectiveness of RFTP
tends to stem from the relatively modest cost
associated with this intervention. 
Conclusions: The evidence suggests that some form 
of RFTP can be effective in improving lower limb
function at any time after stroke, but that the duration
of intervention effect is unclear. There is as yet
insufficient good-quality evidence to make any firm
recommendations for upper limb interventions. If 
task-specific training is used, adverse effects should be
monitored. While the effectiveness of RFTP is relatively
modest, this sort of intervention appears to be cost-
effective. Owing to the large number of ongoing trials,
this review should be updated within 2 years and any
future review should include a comparison against
alternative treatments. Further research should
evaluate RFTP upper limb interventions and in
particular constraint-induced movement therapy,
address practical ways of delivering RFTP interventions,
be directed towards the evaluation of suitable methods
to maintain functional gain, and be powered to detect
whether RFTP interventions are cost-effective.
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Background
The repetitive practice of functional tasks is a
component of current approaches to stroke
rehabilitation. Practice may be augmented by
strategies to enhance learning as used in
movement science approaches, by mechanical
means such as treadmills, or by strategies to
encourage use of the affected limb in daily life by
restraining the unaffected limb. 
All these approaches have a core mechanism based
on the repeated practice of functional tasks. This
has the potential to be a resource-efficient
component of stroke rehabilitation, including
delivery in a group setting, or instructed practice
in the home environment. This review considers
the effectiveness and cost-effectiveness of all forms
of repetitive functional task practice (RFTP).
Objectives
The aims of this study were:
● to determine whether RFTP after stroke
improves limb-specific or global function or
activities of daily living
● to determine whether treatment effects are
dependent on the amount of practice, or the
type or timing of the intervention
● to provide cost-effectiveness estimates for RFTP.
Methods
Data sources
The following searches were undertaken:
● electronic searches of Cochrane Stroke Trials
Register, the Cochrane Library, MEDLINE,
EMBASE, CINAHL, AMED, SportDiscus, ISI
Science Citation Index, Index to Theses,
ZETOC, PEDro and OT Seeker (all from
inception to week 4, September 2006)
● electronic searches on non-English-language
databases and for unpublished trials on
MetaRegister, BioMed Central, CRISP,
Centerwatch, National Research Register,
ReFeR, Stroke Trials Directory, REHABDATA
and CIRRIE (to May 2006)
● searches of conference proceedings, reference
lists of existing systematic reviews, citation
searching, publication on bulletin boards and
author contact for all relevant trials.
Study selection
The review included randomised and quasi-
randomised trials in adults after stroke, which
included an intervention where an active motor
sequence was performed repetitively within a
single training session, where the practice aimed
towards a clear functional goal and where the
amount of task practice could be quantified.
Studies using mechanical or behavioural strategies
to facilitate or encourage functional task practice
were also included. Primary outcomes included
limb-specific or global functional measures.
Secondary outcomes included measures of
activities of daily living and adverse events.
Data extraction
Two reviewers independently screened titles and
abstracts, extracted data and critically appraised
the trials. Assessment of methodological quality
was undertaken for allocation concealment,
blinding, loss to follow-up, trial size and
equivalence of treatment. Trialists were contacted
for additional information.
Data synthesis
Standard Cochrane quantitative systematic 
review methods were used. A fixed-effect model
was used, and results were expressed as 
weighted or standardised mean differences, 
with 95% confidence interval. Subgroup 
analyses were conducted for amount, timing 
and type of intervention, and for adequacy 
of allocation concealment, type of comparison
group, equivalence of therapy time and 
trial size. 
The measures of efficacy of RFTP from the data
synthesis were used to inform an economic model.
The model used a pre-existing data set and tested
the potential impact of RFTP on cost. From the
model an incremental cost per quality-adjusted
life-year (QALY) gained for RFTP was estimated.
Sensitivity analyses around the assumptions made
for the model were used to test the robustness of
the estimates.
Executive summary
xResults
Thirty-one trials with 34 intervention–control
pairs and 1078 participants were included.
Overall, it was found that some forms of RFTP
resulted in improvement in global function, and
in both arm and lower limb function. Overall
standardised mean difference in data suitable
for pooling was 0.38 [95% confidence interval
(CI) 0.09 to 0.68] for global motor function,
0.24 (95% CI 0.06 to 0.42) for arm function
and 0.28 (95% confidence interval 0.05 to 0.51)
for functional ambulation. Results suggest that
training may be sufficient to have an impact on
activities of daily living. Retention effects of
training persist for up to 6 months, but whether
they persist beyond this is unclear. There was
little or no evidence that treatment effects
overall were modified by time since stroke or
dosage of task practice, but results for upper
limb function were modified by type of
intervention. The economic modelling
suggested that RFTP was cost-effective. Given a
threshold for cost-effectiveness of £20,000 per
QALY gained, RFTP is cost-effective so long as
the net cost per patient is less than £1963. This
result showed some sensitivity to the
assumptions made for the model. The cost-
effectiveness of RFTP tends to stem from the
relatively modest cost associated with this
intervention. 
Conclusions
Implications for practice
The evidence suggests that some form of RFTP
can be effective in improving lower limb function
at any time after stroke, but that the duration of
intervention effect is unclear. There is as yet
insufficient good-quality evidence to make any
firm recommendations for upper limb
interventions. If task-specific training is used,
adverse effects should be monitored. While the
effectiveness of RFTP is relatively modest, this sort
of intervention appears to be cost-effective.
Recommendations for future research
Owing to the large number of ongoing trials, this
review should be updated within 2 years. Any
future review should include a comparison 
against alternative treatments. Further research
should:
● evaluate RFTP upper limb interventions and in
particular constraint-induced movement
therapy
● address practical ways of delivering RFTP
interventions
● be directed towards the evaluation of suitable
methods to maintain functional gain
● be powered to detect whether RFTP
interventions are cost-effective, include a
baseline activities of daily living measure,
include indirect costs and use quality of life as
an outcome measure to facilitate economic
analysis.
Executive summary
Description of the condition
The annual incidence of first ever stroke in the
UK is approximately 100,000 people per year.1
Although the incidence of stroke is falling,2 stroke
is still the major cause of long-term neurological
disability in adults.3 The prevalence of disability
and impairment varies according to sampling of
cohorts, but approximately half of all stroke
survivors are left with severe functional problems,4
and 53% are dependent on others for help with
daily activities at 6 months after their stroke.5 Only
5–20% of people with initial upper limb
impairment fully regain arm function, and
30–66% regain no functional use at 6 months.6–9
At 3 weeks and 6 months after stroke, 40% and
15% of people are unable to walk independently
indoors,5 with only 18% regaining unrestricted
walking ability.10 Initial grade of paresis is the
most important predictor for motor recovery, with
a longer recovery period for people with severe
stroke.11
Stroke is thus a leading cause of disability, and as
such contributes to 4% of NHS costs.12 While
stroke is a costly condition in the acute stage, over
40% of the 5-year cost of stroke is likely to be
incurred subsequent to discharge, with 18% of 
the total cost being due to institutional care.13
If the disability and subsequent need for
institutional care can be reduced, there is a
potential for the long-term care costs to be
substantially lowered. 
Description of the intervention
Systematic reviews of treatment interventions for
the paretic upper limb suggest that patients
benefit from exercise programmes in which
functional tasks are directly trained, with less
benefit if the intervention is focused on the
impairment, such as muscle strengthening.14
Although individual studies do not agree whether
increased therapy intensity improves overall
outcome, a recent meta-analysis15 has shown that
more intensive therapy may at least improve the
rate of recovery of activities of daily living (ADLs),
particularly if a direct functional approach is
adopted.16
Repetitive practice of goal-directed, functional
movement under varying conditions for procedural
learning is a feature of many forms of intervention
in stroke rehabilitation. The use of intensive
repetition is grounded in neurophysiological
hypotheses about the reasons for loss of movement
after stroke. Repeated motor practice enhances
motor strength, speed and endurance, while
sensorimotor coupling contributes to the
adaptation and recovery of neuronal pathways.17
Repetitive task training (RTT) is common as a
specific rehabilitation technique, but it is often
combined with techniques to enhance cognitive
involvement in the relearning of motor skills, such
as functional relevance and knowledge of
performance, thereby forming the underlying
principles in the motor relearning or movement
science physiotherapy approach.18
Intensive periods of task practice using shaping
techniques (progressively increasing the difficulty
of a task in small steps and providing frequent
feedback and positive encouragement) to build up
to completion of a functional task are also a major
feature of constraint-induced movement therapy,19
where they are combined with restricted use of the
unaffected limb to overcome learned non-use or
adaptive strategies. 
Intensive practice of functional movement can also
be assisted by treadmills,20 gait trainers21 or
robotics.22 Mechanical assistance is used to
overcome impairment which restricts the ability to
participate, but also serves to deliver an intensity
of training sufficient to develop the amount and
power of movement required for functional
performance. 
Scope of the review
This study will consider the impact and cost-
effectiveness of all three of the major forms of
therapy that have repeated, functional task
practice as a major component, namely repetitive
task training (RTT), constraint-induced movement
therapy (CIMT) and treadmill training (TM). In
combination, these three forms of therapy will be
referred to as repetitive functional task practice
(RFTP).
Health Technology Assessment 2008; Vol. 12: No. 30
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Chapter 1
Introduction
Systematic reviews of TM20 and CIMT23 have
already been published. To provide an overall
picture of the relative effectiveness and cost-
effectiveness of all the common forms of RFTP,
the references from the systematic reviews for TM
and CIMT were followed up and data were
extracted from those primary studies that also met
the inclusion criteria for this study. A systematic
review of RTT studies has already been submitted
to The Cochrane Collaboration by the authors of
this report. This review therefore presents the
results of these three interventions combined. The
characteristics, quality and results of the trials for
each intervention are reviewed and presented
separately to ensure clarity, until combined in
subgroup analysis to present a between-
intervention overall estimate of efficacy and
comparison of effect. 
Scope of the cost-effectiveness
analysis
An economic model will be developed from an
existing data set. The data set contains
information on the natural recovery and resource
use of a cohort of stroke patients, which allows
estimates to be made on outcomes and costs. The
efficacy of RFTP and hence its potential impact on
outcomes will be obtained from the review; the
cost of RFTP will be estimated by considering staff
and equipment costs. Using certain assumptions,
which will be clearly outlined in the methods, the
model data and the efficacy of RFTP from the
review will be used to estimate the cost-
effectiveness of RFTP. Uncertainty in the estimate
will be considered by varying the parameters of
any assumptions that are made.
Objectives
The objectives of this study were to carry out a
systematic review and cost-effectiveness analysis to
determine:
● whether RFTP improves global or limb-specific
functional ability and ADL function in adults
after stroke
● the factors that could influence primary
outcome measures for RFTP, including the
effect of amount, type and timing of
intervention
● estimates of the cost-effectiveness of RFTP. 
Introduction
2
Search strategy for identification
of studies
Electronic searches
The Cochrane Stroke Group Trials Register was
searched in October 2006, using the following
parameters: Intervention Type: “Physiotherapy” or
“Occupational Therapy”, without restriction of
intervention code. 
In addition, the following databases were searched
as follows: The Cochrane Library (2006 Issue 3),
MEDLINE (1966 to September week 4, 2006),
EMBASE (1980 to week 40, 2006), CINAHL (1982
to October week 1, 2006), AMED (1985 to week
40, 2006), SportDiscus (1980 to October week 1,
2006), ISI Science Citation Index (1973 to 14
October 2006), Index to Theses (1970 to
September 2006), ZETOC (to 14 October 2006),
PEDro (to 3 October 2006), OT Seeker (to 21
April 2006) and OT Search (to March 2006). 
The main search design was reviewed by the
Cochrane Stroke Group Trials Search Co-
ordinator. The MEDLINE search given below was
used and adapted for other databases.
MEDLINE (OVID)
1 cerebrovascular disorders/ or exp basal ganglia
cerebrovascular disease/ or exp brain ischemia/
or exp carotid artery diseases/ or
cerebrovascular accident/ or exp brain
infarction/ or exp cerebrovascular trauma/ or
exp hypoxia-ischemia, brain/ or exp
intracranial arterial diseases/ or intracranial
arteriovenous malformations/ or exp
"Intracranial Embolism and Thrombosis"/ or
exp intracranial hemorrhage/ or vasospasm,
intracranial/ or vertebral artery dissection/ 
2 (stroke or poststroke or post-stroke or
cerebrovasc$ or brain vasc$ or cerebral vasc$
or cva$ or apoplex$ or SAH).tw. 
3 ((brain$ or cerebr$ or cerebell$ or intracran$
or intracerebral) adj5 (isch?emi$ or infarct$ or
thrombo$ or emboli$ or occlus$)).tw. 
4 ((brain$ or cerebr$ or cerebell$ or
intracerebral or intracranial or subarachnoid)
adj5 (haemorrhage$ or hemorrhage$ or
haematoma$ or hematoma$ or bleed$)).tw. 
5 hemiplegia/ or exp paresis/ 
6 (hemipleg$ or hemipar$ or paresis or
paretic).tw. 
7 or/1-6 
8 *cerebrovascular disorders/rh or exp *basal
ganglia cerebrovascular disease/rh or exp
*brain ischemia/rh or exp *carotid artery
diseases/rh or *cerebrovascular accident/rh or
exp *brain infarction/rh or exp *cerebrovascular
trauma/rh or exp *hypoxia-ischemia, brain/rh
or exp *intracranial arterial diseases/rh or
*intracranial arteriovenous malformations/rh
or exp *"Intracranial Embolism and
Thrombosis"/rh or exp *intracranial
hemorrhage/rh or *vasospasm, intracranial/rh
or *vertebral artery dissection/rh 
9 *hemiplegia/rh or exp *paresis/rh 
10 exp *gait Disorders, neurologic/rh or *motor
skills disorders/rh
11 rehabilitation/ or "activities of daily living"/ or
exercise therapy/ or occupational therapy/
12 Physical Therapy Modalities/ 
13 Exercise Movement Techniques/ or exercise
therapy/ or walking/
14 Robotics/
15 exp Psychomotor Performance/ 
16 movement/ or gait/ or exp locomotion/ or exp
motor activity/ 
17 "Range of Motion, Articular"/ or "Task
Performance and Analysis"/ or "Practice
(Psychology)"/ 
18 "Recovery of Function"/ 
19 ((motor or movement$ or task$ or skill$ or
performance) adj5 (repetit$ or repeat$ or
train$ or re?train$ or learn$ or re?learn$ or
practic$ or practis$ or rehears$ or rehers$)).tw. 
20 ((motor or movement$ or task$ or skill$ or
performance) adj5 (schedule$ or intervention
or therap$ or program$ or regim$ or
protocol$)).tw. 
21 (functional adj5 (task$ or movement)).tw. 
22 or/8-21
23 7 and 22
The search above was combined with the
Cochrane Stroke Review Group search for
randomised controlled trials.
A similar search (Search 2), given below, was
conducted without limits of study type and/or
client group, to check for trials incorrectly
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indexed, and to trace trials of RFTP in other client
groups for citation tracking. 
MEDLINE OVID
1 *hemiplegia/rh or exp *paresis/rh 
2 exp *gait Disorders, neurologic/rh or *motor
skills disorders/rh 
3 1 or 2
4 Physical Therapy Modalities/ 
5 Exercise Movement Techniques/ or exercise
therapy/ or walking/ 
6 Robotics/
7 rehabilitation/ or "activities of daily living"/ or
occupational therapy/ 
8 exp Psychomotor Performance/ 
9 "Task Performance and Analysis"/ or "Practice
(Psychology)"/ 
10 ((motor or movement$ or task$ or skill$ or
performance) adj5 (repetit$ or repeat$ or
train$ or re?train$ or practic$ or practis$ or
rehears$ or rehers$)).tw. 
11 (functional adj5 (task$ or movement)).tw. 
12 or/4-11
13 movement/ or gait/ or exp locomotion/ or exp
motor activity/ 
14 "Recovery of Function"/ 
15 13 and 14
16 3 and (12 or 15) 
Unpublished trial data were searched for on
national and international databases to May 2006
as follows: MetaRegister of Controlled Trials,
BioMed Central, CRISP, Centerwatch, National
Research Register, ReFeR, Stroke Trials Directory,
REHABDATA and CIRRIE, using simple terms for
stroke and rehabilitation or physical therapy.
Physiotherapy, occupational therapy and robotics
conference proceedings were searched as follows:
● Australian Physiotherapy Association
Conference 2000, 2002, 2004
● Australian Physiotherapy Association Neurology
and Gerontology Physiotherapy Conference 2005
● American Physical Therapy Congress Annual
Conference 2005
● Canadian Physiotherapy Conference 2005
● UK College of Occupational Therapists
Conference 2002, 2003, 2005
● National Association of Neurological
Occupational Therapists Conference 2005
● World Confederation for Physical Therapy 1st
International Congress 1953, 4th International
Congress 1963
● World Confederation of Physiotherapy Europe:
First Congress, Copenhagen 1994:
Physiotherapy in Stroke Management
● Chartered Society of Physiotherapy Annual
Congress 2000, 2001, 2002, 2003, 2004, 2005
● ICORR Rehabilitation Robotics International
Conferences 1999, 2001, 2005
Non-English-language literature was identified by
searching Chinese, Russian and Indian databases
via Eastview, Panteleimon and Indmed, using
broad descriptors for stroke, rehabilitation and
physical therapy. The China National Knowledge
database was searched in both English and
Chinese. Searching and translation of Chinese
abstracts were undertaken by personnel from the
Second Military Medical University, Shanghai.
Other sources
RTT
The reference lists of systematic reviews relevant to
physical or occupational therapy in stroke
rehabilitation were searched.11,14–16,24–45 Reference
lists of publications and literature reviews relevant
to RTT identified by the search were combed to
identify further relevant trials.46–48 In addition,
forward citation searching was undertaken on ISI
Web of Knowledge for all included trials, and the
authors were contacted to ask for details of any
other possible relevant trials, either published or
unpublished. A request for information was also
posted to the bulletin boards of World Congress of
Physical Therapy and PHYSIO JISCmail.
CIMT and TM
Studies relevant to CIMT and TM were sourced
from the search identified above, and also from
existing systematic reviews.20,23 Only those trials of
CIMT and TM that met the requirements of this
review (i.e. RFTP intervention with suitable
comparison) were included.
Inclusion criteria
Types of study
Randomised and quasi-randomised trials (such as
those allocating by date or alternation) were
included in the review. Only the first period of
cross-over trials was included.
One arm of the trial had to include RFTP,
compared against usual practice (including ‘no
treatment’) or an attention-control group. For
trials of TM or CIMT, comparison groups using
alternative forms of training were included.
Examples of attention-control treatment are
comparable time spent receiving therapy on a
different limb or participating in an activity with no
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potential motor benefits. Usual-practice comparison
groups were accepted when the intervention
received by the control group was considered a
normal or usual component of stroke rehabilitation
practices, including neurophysiological or
orthopaedic approaches. Early after stroke it was
assumed that usual practice would mean that
patients would receive some therapy.
Types of participant
Adults (presumed 18 years and older) who had
suffered a stroke were included. Stroke was defined
according to the World Health Organization
(WHO) definition as “a syndrome of rapidly
developing symptoms and signs of focal, and at
times global, loss of cerebral function lasting more
than 24 hours or leading to death, with no
apparent cause other than that of vascular
origin”.49 Trials starting at any time after an acute
stroke and in any setting were included.
Types of intervention
Trials were required to include an intervention
where an active motor sequence was performed
repetitively within a single training session, where
the practice aimed towards a clear functional goal.
Functional goals could involve complex whole
tasks, or pretask movements for a whole limb or
limb segment such as grasp, grip or movement in
a trajectory to facilitate an ADL. To be included,
trials of repetitive activity were required to involve
complex multijoint movement with functional
measurement of outcome, rather than the exercise
of a single joint or muscle group orientated to
motor-performance outcomes. 
Any intensity and duration of task training
schedule was included. However, trials were
included only if the duration or number of
repetitions within a session of practice, and the
number of sessions delivered, could be identified.
Trials clearly using motor relearning as a whole
therapy approach were included if the amount of
task-specific training received could be identified. 
Trials using person-delivered, mechanical or
robotic movement assistance were included if the
purpose of the assistance was to facilitate a task-
related repetition. Trials combining repetitive task
practice with constraint of the unaffected limb
were also included.
Exclusion criteria
Trials were excluded if they combined RFTP 
with other interventions such as electrical
stimulation virtual environments, biofeedback,
bilateral movement, or mental rehearsal. 
Trials were also excluded if the intervention 
used mechanical means simply to increase
endurance through the intensity of practice
without monitoring or adjustment according to
the quality of movement, such as the use of slot
machines.
Trial authors were contacted for clarification of 
the nature of the intervention if it was unclear
whether the trial met the definition.
Types of outcome measure
Primary outcomes
The primary outcomes chosen were global and
limb-specific functional measures. Owing to the
large range of measures used across trials,
selection of outcome measures was done by 
the review authors to maximise quantitative
pooling. If more than one measure was 
available in an outcome category, measures of
functional motor ability used in the primary trials
were prioritised as follows in the different
categories. Items marked with an asterisk are
measures where a low score equals a positive
outcome. In all other measures, a high score
indicates a good outcome.
Upper limb function/reach
● Arm function: Action Research Arm Test
(ARAT), Motor Assessment Scale (MAS) – upper
limb component, Frenchay Arm Test, Wolf
Motor Function Test (WMFT), Functional Test
of the Hemiparetic Upper Extremity (FTHUE),
Box and Block Test (BBT), Test Evaluant des
Membres Supérieurs des Personnes Agées
(TEMPA), University of Maryland Arm
Questionnaire for Stroke, Motor Activity Log
(MAL).
● Hand function: MAS hand, Jebsen Test of Hand
Function*, Peg Test*, Purdue Pegboard.
● Sitting balance/reach: Reaching Performance
Scale, Functional Reach.
Lower limb function/balance
● Lower limb function: walking distance, walking
speed, functional ambulation, sit-to-stand*,
measures of lower limb function, e.g.
Rivermead Mobility Index, Sodring Motor
Evaluation Scale (SMES), Step Test.
● Standing balance/reach: Berg Balance Scale.
Overall functional ability
MAS, Rivermead Motor Assessment (RMA) Scale.
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Secondary outcomes
ADL
Barthel Index (BI), Functional Independence
Measure (FIM), Modified Rankin Scale, Global
Dependency Scale.
Adverse outcome
Pain, injury, falls.
Timing of outcome assessment
Primary outcome timing was at the end of the
intervention period. Where the end of the
intervention period was not clearly defined,
outcome measures at 3 months post-stroke were
chosen as primary. Data are presented for follow-
up less than 6 months post-stroke, and between
6 months and 1 year post-stroke.
Data extraction and assessment of
study validity
Selection of studies
One reviewer (BF) performed the searches. From
the initial references, 4443 obviously irrelevant
items were excluded on title and abstract by one
reviewer (BF) and checked by a second reviewer
(JM). All reviewers (BF, JM, ML and LT)
undertook screening on the same titles and
abstracts until an acceptable level of inter-rater
reliability was achieved (kappa = 0.63). From that
point, two reviewers (from BF, JM, ML and LT)
independently screened references.
In total, 447 full papers considered potentially
relevant were retrieved, including 71 items in
languages other than English. For non-English-
language papers, decisions about exclusion were
made on English abstract or machine translation
of the abstract via WorldLingo or Translation
Booth, if adequate. Where machine translation was
inadequate, or where inclusion was unclear from
English abstracts, the methods sections of full
papers were commercially translated by native
speakers. Seventeen methods sections of papers
and three full non-English-language papers that
were screened as potentially relevant were also
commercially translated. Two reviewers
independently screened all full papers and
methods section translations for non-English
studies. Altogether, 121 papers were progressed to
more detailed filtering by two reviewers (from ML,
LT, BF and JM). 
Data extraction and management
All reviewers (BF, JM, ML and LT) undertook data
extraction and critical appraisal on eight studies.
Using unweighted multiple kappa, inter-rater
reliability of judgement of seven criteria for quality
assessment was median kappa = 0.67 (range
0.48–0.85). Disagreements were reviewed and
instructions for critical appraisal gradings revised.
From that point, two reviewers independently
conducted data extraction and review of the
methodological quality of the eligible trials.
Disagreements were resolved by discussion and
referral to a third reviewer. Data were recorded on
a standardised checklist, incorporating details of
randomisation method, study population,
intervention methods and delivery, reason for
losses to follow-up, and post-therapy and follow-up
outcome measures. In addition, information
relating to treatment monitoring, acceptability and
adherence was extracted where available.
Assessment of methodological quality
Items were evaluated as adequate, inadequate or
unclear, and quality assessment was undertaken
using the following criteria: 
● selection bias
– random allocation
– allocation concealment
– baseline comparability of groups
● performance bias
– equal treatment of groups
● attrition bias
– description of withdrawals, dropouts and
those lost to follow-up
– intention-to-treat analysis
– percentage loss to follow-up
● detection bias
– blinding of outcome assessors.
Analyses
The primary comparison to be undertaken was to
estimate the overall effect of RFTP. Secondary
comparisons were designed to determine whether
treatment effects differed for type of intervention
(RTT, CIMT or TM), or the timing or amount of
intervention. 
Measures of treatment effect
For continuous outcomes using similar
measurement scales, the weighted mean difference
(WMD) with 95% confidence interval (CI) was
used. Where similar outcomes were measured
using different outcome scales, results were
combined using standardised mean difference
(SMD) with 95% confidence interval. Outcomes
measured using both dichotomous and continuous
measurement units were analysed using the
generic inverse variance method. For continuous
outcomes, means of post-therapy scores and their
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respective standard deviations were extracted.
Changes from baseline outcome data were
extracted if available across all trials. 
Unit of analysis issues
Studies with multiple treatment groups
Two RTT trials50–52 compared upper versus lower
limb training, so are included as four
intervention–control pairs. In the subgroup
analyses, these intervention–control pairs are not
included as separate trials, as it was considered
that the impacts of the interventions on upper and
lower limb function in the same person would not
be independent. Results for primary outcome of
the lower limb training groups were selected, as
studies were showing that treatment effects were
greater for lower limbs. This strategy may have the
effect of inflating effect sizes, but the effect should
not bias the tests of subgroup effects. One RTT
trial53 compared upper and lower limb training
groups against the same control group. To avoid
the control group being included twice, and to use
a limb-specific rather than a global or an ADL
measure, the lower limb training versus splint
control comparison was selected for the subgroup
analyses. 
Dealing with missing data
If data were not in a form suitable for quantitative
pooling, trial authors were contacted for
additional information. Attempts were made to
obtain post-therapy scores from trial authors who
had reported median and interquartile ranges
(IQRs).
Assessment of heterogeneity
The degree of heterogeneity for each outcome was
assessed by the I2 statistic. If less than or equal to
50%, any heterogeneity was deemed insubstantial
and a fixed-effects meta-analysis was used. If the I2
statistic was greater than 50%, the individual trial
characteristics were explored to identify potential
sources of heterogeneity. Meta-analysis was then
performed using both fixed- and random-effects
modelling to assess sensitivity to the choice of
modelling approach and reported accordingly. 
Clinical and methodological diversity was
addressed by incorporation of subgroup analyses
for type of participant (time from stroke),
intervention (type and amount of intervention)
and study design (allocation concealment,
comparison group, equivalence of treatment, loss
to follow-up and trial size). 
To test for subgroup effects data were stratified by
subgroup and the Q-statistic was partitioned from
the unstratified analysis into ‘within subgroups’
and ‘between subgroups’. A 2 test of the resulting
between-subgroups Q-statistic was performed,
using a 10% significance level.54
Assessment of reporting biases
Assessment of the potential for reporting bias was
checked by performing a subgroup analysis based
on the trial size (number of participants) and
producing a funnel plot of the standard error (of
effect estimate) against effect estimate. 
Subgroup analysis and investigation of
heterogeneity
Planned subgroup analyses for upper and lower
limb functional outcomes were undertaken as
follows.
● Type of intervention: trials were classified as
RTT, CIMT or TM.
● Dosage of task practice: this was calculated by
multiplying the number of weeks by the number
of sessions per week by the session duration in
hours. Trials were divided into those providing
up to and including 20 hours’ training and
those providing more than 20 hours’ training in
total. The division at 20 hours was based on the
median value for dosage of task practice from
all included trials, and the average length of
stay in the National Sentinel Stroke Audit55
after the first 7 days of acute care, presuming
the provision of 1 hour of training per day in
the inpatient rehabilitation period.
● Time since stroke: mean time since stroke at
recruitment was used to classify trials as within
0–6 months post-stroke or more than 6 months
post-stroke. The division at 6 months was based
on the interpretation of this as the main period
of active rehabilitation. Because a number of
trials recruited very early post-stroke, a post hoc
analysis grouping was included for trials
recruiting within 14 days of stroke. 
It had been intended to consider whether effect
sizes were related to whether training was based
on pre-functional or functional activities or 
pre-intervention level of disability. In the event,
most pre-functional trials were excluded because
they contained passive or active-assisted
movement, and levels of disability proved too
difficult to classify because of mixed groups of
participants and unsuitable measures and data for
this purpose. Therefore, these planned subgroup
analyses are not presented.
The selection of outcome measure for subgroup
analysis was complicated by the fact that few trials
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used similar outcome measures. Subgroup analyses
were performed separately for upper and lower
limb interventions. Outcomes for subgroup
analyses were limited to measures of walking for
lower limbs and arm function for upper limbs. If
more than one measure was available, lower limb
outcomes were prioritised in the following order:
(1) walking speed, (2) walking distance and 
(3) functional ambulation/walking scales; and
upper limb outcomes were prioritised as follows:
(1) ARAT, (2) MAS – upper extremity (MAS-UE),
(3) WMFT and (4) BBT. Outcome selection was
based on evidence for correlation and similar
responsiveness to change for walking distance,
speed and functional ambulation.56 For measures
of arm function, there is evidence for correlation
and similar responsiveness to change for the 
MAS-UE and ARAT,57,58 and for correlation
between ARAT and BBT.59 There is less evidence
for correlation between WMFT and other tests,
but ARAT, BBT and WMFT all correlate well with
the Fugl–Meyer measure of arm impairment.59,60
Four trials61–64 were omitted from the subgroup
analyses because data were unsuitable for pooling.
Of the remaining 27 trials, 26 presented means
and standard deviations, so SMD could be used as
the effect measure. One trial65 was excluded from
the subgroup analyses because it used a
dichotomous main outcome. This trial was
excluded rather than using generic inverse
variance, because SMD is easier for clinicians to
interpret. 
Planned subgroup analyses were also carried out
for allocation concealment (adequate or
inadequate/unclear). In addition, post hoc
subgroup analyses were included to consider the
impact of different comparison groups (attention-
control, usual care), equivalence of therapy time
(equivalent time, additional time) and trial size
(under 25 participants, 25 participants and over),
based on the median value. Planned subgroup
analyses for intervention delivery (therapist versus
self-administered, group versus individual) and
intervention setting (home versus community)
were not undertaken, because of insufficient
numbers of trials.
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8
For the RTT search, 1366 records wereidentified from the Cochrane Stroke Trials
Registry and 18,241 records from the main
database searches, totalling 19,607. A further 772
records were added from unpublished trial
databases, conference proceedings, and hand and
citation searching, totalling 20,379. After removal
of duplicates, 14,978 records progressed to
filtering. 
Figure 1 illustrates that, of the 447 papers
retrieved, 360 studies were excluded as irrelevant
when full-text details were seen. Thirty-four
potentially relevant CIMT and TM studies were
identified from existing systematic reviews,
totalling 121 potentially relevant studies. Forty-
four studies were excluded after more detailed
filtering, leaving 77 studies identified as
potentially appropriate for inclusion. Of these,
eight are ongoing studies, of which one was
identified from the Cochrane Stroke Trials
Registry, four from handsearching, two from
secondary referencing, and one from author
contact. Thirty-eight studies are still awaiting
assessment, because available information is
insufficient to be able to make a decision. Seven of
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Potentially relevant titles identified by 
RTT search (n = 14,978)
Full text papers retrieved for 
more detailed evaluation 
(n = 447)
Potentially relevant 
studies identified 
from CIMT and TM 
systematic reviews 
(n = 34)
Studies excluded 
as not relevant 
(n = 360)
Potentially appropriate studies 
to be included in the 
meta-analysis (n = 77)
Studies included in meta-analysis 
(n = 31)
Studies excluded (n = 44)
• not functional, no functional outcome (n = 9)
• mixed/exercise interventions (n = 11)
• not repetition (n = 3)
• passive movement (n = 1)
• unsuitable comparison (n = 11)
• methodological or reporting reasons (n = 9)
• Ongoing studies (n = 8)
• Awaiting assessment: insufficient information (n = 38)
FIGURE 1 Flowchart of included and excluded studies
these were identified from the Cochrane Stroke
Trials Registry, 20 from handsearching, three from
database searching, five from secondary references
and three from author contact. 
Unpublished data were sourced from the trial
authors for 11 RTT trials50,51,53,65–72 and two
CIMT trials.73,74
All of the included studies for RTT were identified
from the Cochrane Stroke Trials Registry. For
CIMT and TM, all of the included studies were
identified from existing systematic reviews, except
for one recent CIMT trial identified from the
Cochrane Stroke Trials Registry.75
Description of studies
Thirty-one studies were included in total,
including 34 intervention–control pairs and data
from 1078 participants relevant to this review. A
description of included studies is presented
separately for each of the three forms of RFTP,
namely RTT, CIMT and TM. A summary of the
characteristics of the included studies is given in
Appendices 1–3.
Included studies
RTT
Fourteen trials were identified, comprising 17
intervention–control pairs, which met the
inclusion criteria. Three trials included two
relevant intervention–control pairs: Kwakkel and
colleagues53 refer to a trial with two
intervention–control pairs: a lower limb training
group versus splint control, and an upper limb
training group versus splint control.
Blennerhassett and Dite50 also include two
intervention–control pairs: an upper limb training
group versus lower limb attention-control, and a
lower limb training group versus an upper limb
training attention-control. Two papers report on
two intervention–control pairs of the same trial:
Salbach and colleagues51 refer to a lower limb
training group versus upper limb training
attention-control, and Higgins and colleagues52
refer to an upper limb training group versus lower
limb training attention-control. 
In one trial71 there were three arms, consisting of
a functional task practice group, a strength
training group and a usual-care group. Only the
data for the intervention–control pair of functional
task practice versus control are included here. 
Design
The 14 trials considered comprised 13 randomised
controlled trials (RCTs)50,51,53,65–68,70–72,76–78 and
one quasi-randomised trial.69 Four of the trials
were identified as pilot RCTs67,71,76,77 and three of
the trials were multicentre.51,53,77 Three of the
trials were stratified for randomisation: one for
baseline level of walking deficit,51 one for gender
and side of stroke,68 and one for severity of
deficit.71
Sample size
Four trials had 25 participants or fewer,66,67,69,76
six trials had between 25 and 49
participants,50,65,71,72,77,78 and five trials had 50
participants or more.51,53,68,70,71
Setting
Of the 14 trials, three were carried out in
Canada,51,65,67 three in Australia,50,66,78 three in
the UK,69,70,77 one in Taiwan,72 one in the USA,71
one in The Netherlands53 and one in France.76
CIMT
Eleven trials met the inclusion criteria. In four
trials61,62,79,80 there were three arms consisting of a
modified CIMT group, a traditional rehabilitation
group and a no-treatment control group. In two of
these trials the traditional rehabilitation group
also received RTT, with the only difference
between groups being constraint.79,80 In these trials,
therefore, the no-treatment group was included as
the comparison group. In the remaining two trials
the data for the modified CIMT and traditional
rehabilitation groups were included.61,62
Design
All 11 trials were identified as RCTs, of which two
were identified as pilot81,82 and two as
preliminary,61,83 and one trial was labelled a
‘feasibility and efficacy’ study.80 All trials were
single centre.
Sample size
Ten trials had 25 participants or fewer.61,62,73,74,79–84
One trial had 50 participants or more.64
Setting
Nine trials were carried out in the
USA,61,62,73,74,80–84 one in Saudi Arabia79 and one
in Thailand.64
TM
Six trials were identified which met the eligibility
criteria. One trial with three arms consisted of two
TM interventions, speed-dependent TM and
limited progressive TM, compared with
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conventional gait training.85 The limited
progressive TM group was used in this review, as
speed-dependent TM was judged to comprise two
mechanisms of action.
Design
One study was a cross-over trial,63 of which only
the first phase was used. The remaining five
studies were RCTs. Of these five trials, one was
identified as a pilot controlled trial.86 All of the
trials were single centre. Three of the trials were
stratified for randomisation, one for walking
speed,87 one for deficit severity and age,88 and one
for initial time to walk 10 m without assistance.85
Sample size
Two trials had 25 participants or fewer,63,86 one
trial had between 26 and 49 participants,87 and
three trials had 50 participants or more.85,88,89
Setting
Of the six trials, two were carried out in the
USA,86,88 three in Germany;63,85,89 and one in
Australia.87
Participants
RTT
The 14 trials included 680 participants, of which
659 were included in the 17 intervention–control
pairs relevant to this review. All of the trials
included both genders, with three trials having
more than 60% male participants.51,65,66 In two
trials, the participants had a mean age of less than
6050,69 and in five trials the mean age was over
70 years.51,68,70,77,78
Six trials included only participants after a first
stroke53,67,68,71,72,76 and two trials included
participants with either first or recurrent
stroke.50,51 In the remaining trials, it was unclear
whether inclusion was limited to first stroke only. 
Mean time since stroke
Three trials recruited within 14 days of stroke.53,68,70
A further four trials recruited within the first
month post-stroke,65,71,76,77 one trial recruited
within 3 months of stroke,50 two trials 
recruited within 6 months of stroke,69,78 two 
trials recruited within 12 months of stroke51,72
and two trials recruited participants in the 
chronic phase of stroke.66,67
CIMT
The 11 trials included 203 participants, and data
from 190 participants were relevant to this review.
Thirteen participants were not included from
studies where there was more than one
comparison group.61,62,79,80 All of the studies
included both genders, with six studies having
more than 60% male participants.61,62,64,74,82,84 In
four trials, participants had a mean age of less
than 60 years;62,64,79,80 no trials had a mean age
over 70 years.
Three trials included only subjects after a first
stroke.64,74,83 In the remaining trials, it was unclear
whether inclusion was limited to first stroke only.
Mean time since stroke
Three trials recruited within 19 days of
stroke,81,82,84 three trials recruited between 1 and
6 months post-stroke,61,79,80 and one trial recruited
between 3 and 9 months post-stroke.83 The
remaining trials recruited 12 months or more
post-stroke.62,64,73,74
TM
The six studies included 254 participants, of which
data from 229 participants were relevant to this
review. Five of the studies included both genders,
as participants in one study were all male.86 Five
studies had more than 60% male
participants.63,85–87,89 Two trials had a mean age
less than 60;85,86 no trials had a mean age more
than 70 years.
Three trials included only subjects after a first
stroke,63,87,89 one trial included subjects with either
first or recurrent stroke,85 and in the remaining
two trials86,88 it was unclear whether inclusion was
limited to first stroke only.
Mean time since stroke
One trial recruited within the first month of
stroke,86 one trial recruited within 3 months 
post-stroke,89 one trial recruited within 6
months post-stroke85 and three trials recruited 
in the chronic phase of stroke recovery.63,87,88
Interventions
RTT
Two trials used whole therapy motor
approaches,68,70 and four trials trained single
tasks, all related to balance, reach or sit-to-
stand.65,66,76,77 The remaining trials consisted of
mixed functional task training. Of these, three
used a circuit-training approach.50,51,67 While all of
the remaining trials included some functional task
practice, this was sometimes mixed with other
components, including strengthening exercise and
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TM,53 upper limb exercise,69 lower limb exercise78
and shaping training.72
Of the 17 intervention–control pairs relevant to
this review, four included lower limb or mobility
training,50,51,53,67 one trained sit-to-stand
movements,65 two trained balance in sitting and
standing,76,77 one trained functional reach in
sitting,66 and one trained standing balance and
mobility.78 Six intervention–control pairs were
upper limb training.50,52,53,69,71,72 Two
intervention–control pairs used whole therapy
approaches, training global function.68,70
Setting
Four trials were carried out solely in an inpatient
setting,50,65,76,77 four trials included both inpatient
and outpatient care,53,68,70,71 four trials were carried
out in outpatient or community settings51,66,67,72
and two trials were in the home environment.69,78
In three trials, the intervention was additional to
usual care, of which two were during inpatient
rehabilitation71,77 and one was after discharge
from inpatient therapy, but additional to
outpatient therapy.69
Amount of task practice
The number of hours of training varied
considerably across the interventions. Three trials
provided less than 10 hours’ training in
total,66,70,77 seven trials provided between 10 and
21 hours’ training,50,51,65,67,68,71,76 two trials
provided more than 40 hours’ training53,72 and
two trials prescribed more than 40 hours’ home-
exercise therapy.69,78
Duration of training
The length of time over which training was spread
varied from 2 to 4 weeks for seven
trials.50,66,67,71,72,76,77 For two trials, the length of
time was estimated as 3 weeks of hospital inpatient
therapy, with therapy for some patients in an
outpatient setting if required.68,70 The intervention
in four trials was over 6–8 weeks51,65,69,78 and in
one trial the intervention was over 20 weeks.53
Intervention delivery
All of the interventions were delivered by trained
physiotherapists or occupational therapists, except
for the self-monitored home-exercise
programmes,69,78 where trained staff input was
restricted to prescription and programme review,
one trial where trained physiotherapy assistants
provided balance training77 and one trial where
registered practical nurses delivered sit-to-stand
training.65 Three of the interventions were
delivered in a group setting of between four and
seven participants per group.50,65,67
Of those programmes delivered in a circuit-class
format, trial authors reported between 70 and
80% compliance.50,51,67 For the self-administered
programmes in a home setting, trial authors
reported 68–75% self-monitored adherence to the
prescribed exercise programme.69,78
CIMT
Trials were divided into those evaluating
CIMT64,73,74,83,84 and those evaluating modified
CIMT (mCIMT).61,62,79–82 CIMT interventions
included wearing a padded mitten and/or sling to
reduce use of the unaffected arm, together with a
programme for improving task performance of the
affected limb using techniques such as ‘shaping’
(progressively increasing the difficulty of a task in
small steps and providing frequent feedback and
positive encouragement) and repetitive task
practice. Typically, therapy sessions lasted for
6 hours with participants attending 5 days per
week. mCIMT comprised similar interventions, but
therapy time was reduced to typically 1 hour per
day with participants attending 3 days per week.
Setting
Two trials were carried out solely in an inpatient
setting,81,82 and one trial included both inpatient
and outpatient care.84 Seven trials were conducted
in outpatient clinic settings,61,62,64,73,74,79,80 and the
final study83 did not specify a setting, but given
that participants were 3–9 months post-stroke it is
likely to be an outpatient clinic setting.
Amount of task practice
The number of hours of training varied across
trials, with those evaluating CIMT typically
providing a larger number of hours, with a
minimum of 42 hours84 and a maximum of
75 hours.74 Modified CIMT trials typically provided
30 hours’ training;61,62,79,80 with the exceptions of
one trial where 15 hours’ training was provided,82
and another providing 20 hours’ training.81
Duration of training
All CIMT trials spread training over 2 weeks, with
the exception of one trial84 where training
spanned 2.5 weeks. Trials evaluating mCIMT
spread training over a longer period, typically
10 weeks,61,62,79,80,82 with the exception of one
trial81 where training lasted for 2 weeks.
Intervention delivery
Interventions in eight trials were delivered by
trained physiotherapists and/or occupational
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therapists,61,62,79–84 with one trial also including
delivery by ‘therapy assistants’.84 In three trials it
is unclear who delivered the intervention.64,73,74
In the majority of trials, it is not clear whether
interventions were delivered on a one-to-one or
group basis. Exceptions are one trial where
treatment was on a one-to-one basis,83 and one
trial where participants were treated in groups of
three to four.64
TM
Two studies evaluated unsupported TM,87,88 and
four studies evaluated bodyweight-supported
treadmill training.63,85,86,89 One trial supported
bodyweight to a maximum of 15%,89 one trial only
allowed bodyweight support in the first three
training sessions,85 and one trial progressively
decreased bodyweight support as participants
acquired greater self-support.86
Two trials practised walking training with either a
defined training heart rate89 or a target heart rate
of 60–70%.88 The other trials did not specify a
defined heart rate. 
Five trials increased the belt speed of the treadmill
during the intervention. One trial identifies the
use of a treadmill with a variable belt speed, but
does not specify how this was used.63
Setting
Four trials were carried out in an inpatient
setting63,85,86,89 and two trials in an outpatient
setting.87,88 The four trials in the inpatient setting
were in addition to usual care.
Amount of task practice
Only one trial provided more than 20 hours’ task
practice.88
Duration of training
The length of time over which training was spread
varied from 2 to 4 weeks for four studies.63,85–87
For one study the length of time was 6 weeks89 and
for one study it was 6 months.88
Intervention delivery
All of the interventions were delivered by trained
physiotherapists or occupational therapists.
Comparison interventions
RTT
Ten intervention–control pairs compared the
intervention against an attention-control: two
intervention–control pairs used a recreation or
cognitive therapy control group,65,66 two
intervention–control pairs from the same trial
used a splint control53 and six (four from two
trials) used a comparison training programme for
the upper or lower limb.50,51,67,78
Seven intervention–control pairs compared the
intervention against usual care. Of these, three
were during inpatient rehabilitation and provided
equivalent hours of therapy,68,70,76 and one
provided additional hours of therapy.71 The other
three intervention–control pairs were after
discharge from inpatient rehabilitation, and
additional to any outpatient treatment.69,72,78 It is
unclear whether the duration of therapy for the
intervention–control pair was equivalent for one of
these trials.72
CIMT
Three studies compared the intervention against
an attention-control. One trial used a bimanual
neurodevelopmental therapy control group,64 one
trial used procedures designed to focus attention
on the affected limb without providing training in
active movement,73 and one trial used a control
designed to be less intense and designed to
improve task performance with the unaffected
side.74
Three trials compared the intervention against
usual care only.81,82,84 Control groups received an
equal frequency of therapy time in two trials,81,84
and in one trial control participants received half
the amount of therapy time compared with
intervention participants.82
A further three trials had two comparison groups,
one receiving usual care and one receiving no
treatment.61,62,80 Usual-care participants in all
three trials received an equal amount of therapy to
the intervention group; the no-treatment group
received no interventions during the same period.
Another trial also had two comparison groups, one
receiving no treatment, the other an attention-
control group that received the intervention
without the restraint component.79
The trial by Alberts and colleagues83 compared
the intervention to no treatment, with participants
randomised to the latter receiving the intervention
1 year later.
TM
One trial compared the intervention against 
an attention-control consisting of a home-exercise
programme to lengthen and strengthen 
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muscles.87 Two trials compared against an
alternative intervention.88,89 One of these
interventions was individual physiotherapy
concentrated on walking rehabilitation,89 and one
was based on common components of
conventional therapy which would not normally
have been received as participants were late post-
stroke.88 Three trials compared the intervention
against usual care.63,85,86 These trials were during
inpatient rehabilitation and provided equivalent
hours of therapy.
Primary outcomes
The 31 included trials used a wide range of
different outcome measures, measurement
statistics and time intervals for follow-up. Measures
selected post-intervention are detailed below.
Upper limb functional outcome
measures
Arm
● RTT: ARAT,53 WMFT,72 MAS – arm,50,68,70
BBT,52 FTHUE71 and Southern Motor Group
Assessment – upper limb activity.69
● CIMT: Action Research Arm Test61,62,64,79,80,82
and WMFT.61,73,74,79–81,83
Hand function
● RTT: Nine Hole Peg Test (9HPT),52 Ten Hole
Peg Test (10HPT),69 MAS – hand.50,68,70
● CIMT: Grooved Pegboard Test,84 a key-turning
task,83 and hand grip and pinch strength.64
Sitting balance/reach
● RTT: reaching distance,66 Sitting Equilibrium
Index,76 MAS – balanced sitting,68,70 and lateral
reach – time to return to quiet sitting.77
Lower limb functional outcome
measures
Walking distance 
● RTT: Six Minute Walk Test (6MWT).50,51,67
● TM: 6MWT87–89 and Five Minute Walk Test.86
Measures of walking distance over 5 minutes
were converted to distance over 6 minutes, on
the assumption that participants could maintain
effort equivalently over such similar periods. 
Walking speed
● RTT: Ten Metre Walk Speed (10MWS) with
walking aid,53,66,67 Five Metre Walk Speed
(5MWS) at comfortable speed51 and Six Metre
Walk Speed (6MWS).70
● TM: 5MWS,86 10MWS85,87,89 and walking speed
over 30 feet (9.1 m).88
Functional ambulation
● RTT: Functional Ambulation Classification
(FAC)53,76 and MAS – walking.68,70,78
● TM: FAC.85,86
Sit-to-stand
● RTT: Timed Up and Go (TUG),50,51,67
MAS – sit-to-stand,68,70 sit-to-stand time in
seconds,77 and number of people able to 
stand safely and independently on two
occasions.65
Lower limb functional measures
● RTT: SMES trunk, balance and gait subscale,68
Step Test,50,67 and Rivermead Leg and Trunk.70
Standing balance and reach
● RTT: Upright Equilibrium Index,76 Functional
Reach78 and Berg Balance Scale.51
● TM: measures of standing balance using an
instrumented balance assessment system88
which was not used.
Global motor function
● RTT: MAS68 and RMA score for gross
functions.70
● CIMT: none
● TM: RMA score for gross functions.63,88,89
Secondary outcomes
ADL measures
● RTT: BI51,53,68,70 and FIM.76 Two trials used the
BI scoring out of 20,53,70 while the other trials
used the scoring out of 100.
● CIMT: The BI.81
● TM: none.
Adverse events
● RTT: number of falls.65
● CIMT: levels of stiffness and discomfort on the
affected side.73
● TM: no trials reported quantitative data for
adverse events. Narrative reports and reasons
for withdrawal are summarised. 
Timing of outcome measurement
● RTT: within the 0–6-month period post-stroke:
one trial77 measured outcome at 1 month 
post-intervention and three trials at 2 months
post-intervention.67,76,78 Within the 6–12-month
post-stroke period, one trial measured outcome
at 6 months post-intervention,50 one trial at
9 months post-intervention,71 one trial at
6 months post-randomisation,70 and one trial at
1 year post-stroke.68
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● CIMT: one trial measured outcome 3–4 months
post-stroke84 and one trial measured outcome
6 months post-intervention.74
● TM: two trials measured outcome at 3 months
post-intervention.87,89
Excluded studies
There is a large number of excluded studies
(n = 44), described in Appendix 4. Because of the
difficulties in determining whether trial
interventions included task-specific functional
repetition, the authors have attempted to be as
transparent as possible about the basis on which
trials were excluded. The reasons for exclusion were:
● not functional, or no functional outcome: nine
studies 
● mixed interventions, or interpreted as focusing
predominantly on exercise: 11 studies
● not repetition, or unable to determine amount
of practice: three studies
● passive movement: one study
● comparison group also includes some form of
repetitive functional intervention: 11 studies
● methodological or reporting reasons: nine studies.
The excluded studies included three trials that
had been either partially or fully translated from
Chinese to English. While translation was
undertaken by native-speaking health-service
workers, there is the possibility that information
was misinterpreted or misunderstood.
Ongoing studies
There are eight ongoing studies, where the
information available is sufficient to say that the
interventions include an element of RFTP. These
are detailed in Appendix 5. Three trials involve
training for standing, balance or sit-to-stand,90–92
two trials are of lower limb circuit training93,94 and
one trial is of upper limb task-specific training.95
One trial uses a motor relearning approach
(Langhammer B, Oslo University College, Oslo,
Norway: personal communication, November
2006) and one trial is of CIMT.96 All are with
participants in the early stages of stroke recovery,
except for the trial by Langhammer.
Studies not assessed at report
completion
RTT
Of the 17 studies categorised as unable to be
assessed, 12 were ongoing studies identified from
trials registers, where the information available
was insufficient to be able to exclude them at this
stage.97–108 Two studies are unpublished, and the
reviewers are awaiting data.109,110 One study was
published as a conference proceeding, and the
reviewers were unable to contact the authors.111
Two studies are published, and attempts are being
made to contact the authors to determine the
exact content of the intervention.112,113
CIMT
Of the seven studies awaiting assessment, three are
ongoing114,115 (Page S, University of Cincinnati
Academic Medical Centre, Ohio, USA: personal
communication, February 2007). One recently
published study was not in the date range for
searching.75 Two related studies have recently
completed and been submitted for publication.116
The reviewers were unable to contact the authors
of one study to assess for eligibility.117
TM
Of the 14 studies awaiting assessment, the
information available for seven ongoing studies is
insufficient to be able to exclude them at this
stage.118–124 Three studies require
translation.125–127 One study is recently
completed128 as a follow-up to an included study,86
and three studies could not be traced.129–131
Quality of included studies
Allocation
RTT
Allocation concealment was adequate in eight
trials.50,51,53,67,70,71,77,78 In five trials, allocation
concealment was unclear; of these, three trials
stated that random allocation was used, but
provided no description of the procedure for its
concealment from those recruiting
participants;68,72,76 one trial used coin flipping to
randomise participants with no further description
of the procedure,65 and one trial attempted
concealment with a procedure involving
participants drawing cards out of a box containing
ten control group and ten experimental group
cards, but the procedure for ensuring that those
recruiting participants remained unaware of
assignments is not described.66 One trial was quasi-
randomised, allocating participants to intervention
or control groups in alternate runs of five.69
CIMT
The procedure for allocation concealment was
unclear in all trials. Seven trials stated that random
allocation was used, but provided no description
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of the procedure.61,62,73,79,80,83,84 Four trials stated
use of tables of random numbers to allocate
participants to intervention or control groups, with
no description of the procedure.64,74,81,82
TM
Allocation concealment was adequate in four
trials.86–89 In two trials, allocation concealment was
unclear. One trial stated that participants were
assigned to groups by block randomisation on the
basis of walking speed, but provided no
description of the procedure for concealing the
allocation, or the block length.85 One trial stated
randomisation, with no description of the
procedure.63
Blinding of outcome assessors
RTT
Blinding of primary outcome assessment was
stated in all but two trials.69,71 Of the studies that
stated observer blinding, three gave no details of
how this was done.68,72,78 Four trials checked
whether the outcome assessor had become
unblinded,51,53,67,70 and out of these, three trials
reported that some degree of unmasking might
have occurred.51,53,67
CIMT
Blinding of outcome assessment was attempted in
all trials with the exception of one trial,79 where
there was no mention of blinding. In two trials73,84
action taken at blinding was judged likely to have
been effective, for example employing personnel
from outside the hospital who were blind to
treatment assignment. Eight trials stated that
outcome assessment was blinded, but did not
describe the procedure.61,62,64,74,80–83 No trial
reported checking for the possibility that
unblinding had occurred.
TM
Blinding of primary outcome assessment was
stated in two trials.85,87 Neither trial described
checks for unblinding. Two trials attempted
blinding, but report that this may not have been
successful,88,89 for example one trial stated that as
a result of staffing limitations and institutional
safety regulations, treadmill exercise testing was
conducted by the same staff who provided
training,88 hence metabolic fitness tests were
unblinded. In one trial, physiotherapists not
involved in the therapy were responsible for the
assessment of the RMA Scale, but disclosure by
patients and team-mates could not be fully
excluded.89 One trial did not mention blinding of
outcome assessors to participants’ treatment
status.86
Owing to the nature of the interventions, blinding
of participants, intervention providers or usual
care providers was not assessed, as it is essentially
impractical in this type of study.
Follow-up and exclusions
RTT
All trials provided information about numbers of
withdrawals and reasons for withdrawal. All trials
accounted for all participants at the end of the
trial, except for one, which included participants
in the analysis only if they completed the
treatment programme.71 Of the 14 trials in total,
three trials had 10–20% loss53,68,78 and two trials
had more than 20% loss.67,70 The remaining nine
trials had less than 10% loss to follow-up.
CIMT
Nine trials had no withdrawals.61,62,64,73,74,79,80,82,83
One trial provided information about numbers of
withdrawals and reasons for withdrawal;84 and one
trial81 states overall numbers of withdrawals, but
not by intervention group. All except one trial81
accounted for all participants at the end of the
trial. All trials had no loss to follow-up, except for
one trial with 13% loss81 and one trial with 29%.84
TM
Five trials provided information about numbers of
withdrawals and reasons for withdrawal, and
accounted for all participants at the end of the
trial. Withdrawals and follow-up were unclear in
one trial.63 Two trials had less than 10% loss to
follow-up post-treatment,87,89 two trials had
11–20% loss to follow-up post-treatment85,86 and
one trial had more than 20% loss to follow-up
post-treatment.88
Other potential sources of bias
To detect systematic differences in care provided
to participants in comparison groups other than
the intervention under investigation, trials were
assessed to determine whether groups were treated
equally during the intervention and during usual
care. 
RTT
During the intervention, groups were treated
equally in all trials, with the following exceptions:
in one trial70 there was no significant difference in
the amount of treatment; however, the authors
state in a supplementary paper that there may
have been differences in elements of treatment
such as detailed feedback and social
conversation;132 in one trial it is not clear whether
groups were treated equally72 and in two trials
participants in the intervention group received
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additional hours of therapy.71,77 During usual care,
groups were treated equally in eight
trials.50,53,65–69,77 In four trials no information is
provided70–72,76 and in a further two trials52,78
there was no usual-care group.
CIMT
During the intervention, comparison groups
receiving therapy were treated equally in all except
two trials. In one trial,73 participants in the
intervention group spent 7 hours at the
rehabilitation centre each weekday for 2 weeks;
the comparison group received only four 
10-minute periods encouraging them to focus on
performing new activities with the affected upper
extremity at home and two sessions of ‘physical
therapy’, plus a range of exercises to carry out at
home. (As it was unknown how long control group
participants practised, equivalence of therapy time
was assumed for subgroup analyses.) In another
trial,74 participants in the intervention arm of the
trial similarly received longer periods of therapy
(6 hours per day over 8 weekdays and 4 hours per
day over 2 weekend days) than the comparison
group (3 hours per day over 8 weekdays and
2 weekend days of rest). Groups were treated
equally in all trials with a usual-care comparison.
TM
During the intervention, other than the
intervention provided, groups were treated equally
in all except one trial,87 where the control group
was given a home-exercise programme to carry
out for the same number of sessions as in the
intervention group. However, this programme was
not prescribed in sufficient number or intensity to
provide a training effect and instead aimed to
provide a credible sham programme. Groups were
treated equally in all trials with a usual-care
comparison. 
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Primary outcomes
Results are presented separately for upper and
lower limb outcomes and global function,
concluding with an overall treatment effect for all
forms of RFTP on functional outcome. All results
are post-therapy, except for Langhammer and
Stanghelle,68 which are 3 months post-stroke, and
Van Vliet and colleagues,70 which are 3 months
post-baseline. 
Upper limb function: 
post-therapy
Results are presented for arm function, hand
function, and sitting balance and reach. 
Arm function
Eighteen trials recruiting 634 participants
measured arm function, with data suitable for
pooling available for 76% (n = 485) (Figure 2).
There was some heterogeneity of treatment effects
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Chapter 4
Results of the review
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 02 Upper limb function
Outcome: 01 Arm function
Study  Treatment  Control SMD (fixed)  Weight (SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 RTT
Blennerhassett, 200450   15        4.90 (1.90)        15        5.10 (1.50)       6.45 –0.11 (–0.83 to 0.60)      
Higgins, 200652   47      29.00 (17.00)      44      28.00 (19.00)     19.58   0.06 (–0.36 to 0.47)      
Kwakkel, 199953   27      20.00 (22.00)      34      10.00 (19.00)     12.59   0.48 (–0.03 to 1.00)      
Langhammer, 200068   29        4.70 (2.00)        24        4.10 (2.30)      11.21   0.28 (–0.27 to 0.82)      
Turton, 199069   12      13.83 (6.00)        10      12.25 (7.20)       4.66   0.23 (–0.61 to 1.07)      
Van Vliet, 200570   42        3.88 (2.23)        43        3.69 (2.38)      18.30   0.08 (–0.34 to 0.51)      
Winstein, 200471   20        9.58 (5.70)        20        9.47 (6.30)       8.62   0.02 (–0.60 to 0.64)      
Yen, 200572   13      –2.57 (0.93)        17      –3.06 (1.54)       6.24   0.36 (–0.37 to 1.09)      
Subtotal (95% CI) 205                               207  87.66   0.17 (–0.03 to 0.36)
Test for heterogeneity: 2 = 3.18, df = 7 (p = 0.87), I2 = 0%
Test for overall effect: Z = 1.67 (p = 0.09)
02 CIMT
Alberts, 200483     5    –28.89 (24.80)        5    –25.02 (17.96)      2.14 –0.16 (–1.40 to 1.08)      
Atteya, 200479     2      52.00 (6.00)          2      51.50 (10.50)      0.85   0.03 (–1.94 to 2.00)      
Dromerick, 200081   11      52.80 (5.90)          9      44.30 (11.10)      3.75   0.95 (0.01 to 1.89)        
Page, 200180     2      53.00 (6.00)          2      51.00 (10.00)      0.74   0.14 (–1.97 to 2.25)      
Page, 200582     5      49.80 (3.27)          5      35.80 (3.56)       0.56   3.70 (1.28 to 6.12)        
Taub, 199373     4        8.10 (0.42)          5        6.90 (0.70)       1.13   1.79 (0.07 to 3.50)        
Wittenberg, 200374     9        7.54 (2.04)          7        5.85 (2.79)       3.16   0.67 (–0.35 to 1.69)      
Subtotal (95% CI)   38                                 35  12.34   0.77 (0.26 to 1.29)
Test for heterogeneity: 2 = 10.18, df = 6 (p = 0.12), I2 = 41.0%
Test for overall effect: Z = 2.93 (p = 0.003)
Total (95% CI) 243                               242 100.00      0.24 (0.06 to 0.42)
Test for heterogeneity: 2 = 17.99, df = 14 (p = 0.21), I2 = 22.2%
Test for overall effect: Z = 2.59 (p = 0.010)
–10 –5 0 5 10
 Favours control  Favours treatment
FIGURE 2 Arm function
(I2 = 22.2%), although not sufficient to merit the
use of a random-effects approach. 
Eight RTT trials recruited 467
participants,50,52,53,68–72 with data available for 88%
(n = 412) of participants. Ten CIMT trials
recruiting 167 participants measured arm
function.61,62,64,73,74,79–83 In three of the CIMT
trials with 91 participants in total, data were
unsuitable for pooling.61,62,64 Page and colleagues
(2002)61 included outcome data for nine
participants, and provided means with no
standard deviations (ARAT: CIMT group mean
change +11.5, traditional therapy group mean
change +1.4). Page and colleagues (2004)62
included data for 13 participants, and also
provided means with no standard deviations
(ARAT: CIMT group mean change +11.4,
traditional therapy group mean change +7.1).
Suputtitada and colleagues64 reported median and
ranges for 69 participants (ARAT: CIMT group
n = 33, median 55, range 30–57, control group
n = 36, median 47.5, range 15–54). Of the
remaining seven CIMT trials with 76 participants,
data were available for 96% (n = 73). 
The pooled effect for the impact of RFTP on arm
function across all trials showed a small effect size,
which was statistically significant: (SMD 0.24, 
95% CI 0.06 to 0.42).
Hand function
Seven trials recruiting 357 participants measured
hand function, with data available for 86%
(n = 307) (Figure 3). Five RTT trials recruited 324
participants,50,52,68–70 with data available for 87%
(n = 281) of participants. Two CIMT trials83,84
recruited 33 participants, with data available for
79% (n = 26). The pooled effect for RFTP on
hand function across all trials was small, and
marginally statistically non-significant (SMD 0.19,
95% CI –0.03, 0.42).
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 02 Upper limb function
Outcome: 02 Hand function
Study
or subcategory
 Treatment  Control SMD (fixed)
(95% C)
Weight
 (%)
SMD (fixed)
(95% CI)N Mean (SD) N Mean (SD)
01 RTT
 Blennerhassett, 200450
 Higgins, 200652
 Langhammer, 200068
 Turton, 199069
 Van Vliet, 200570
Subtotal (95% CI)
Test for heterogeneity: 2 = 1.66, df = 4 (p = 0.80), I2 = 0%
Test for overall effect: Z = 1.36 (p = 0.18)
02 CIMT
 Alberts, 200483
 Boake, 200684
Subtotal (95% CI)
Test for heterogeneity: 2 = 0.00, df = 1 (p = 0.99), I2 = 0%
Test for overall effect: Z = 1.36 (p = 0.17)
Total (95% CI)
Test for heterogeneity: 2 = 2.50, df = 6 (p = 0.87), I2 = 0%
Test for overall effect: Z = 1.69 (p = 0.09)
9.90
29.71
17.10
  7.19
 28.04
 91.93
  
3.11
  8.07
  4.96
100.00
–0.08 (–0.80 to 0.63)
  0.28 (–0.13 to 0.70)
  0.33 (–0.21 to 0.87)
–0.11 (–0.95 to 0.73)
  0.09 (–0.33 to 0.52)
  0.16 (–0.07 to 0.40)
  
  0.55 (–0.72 to 1.83)
  0.55 (–0.47 to 1.56)
  0.55 (–0.24 to 1.34)
  0.19 (–0.03 to 0.42)
–4 –2 0 2 4
Favours
control
Favours
treatment
  15     4.70 (2.50) 15     4.90 (2.10)
  47   –9.00 (3.00) 44 –10.00 (4.00)
  29     4.60 (1.90) 24     3.90 (2.30)
  12 –43.50 (20.80) 10 –41.10 (20.10)
  42     4.30 (2.41) 43     4.07 (2.56)
145  136
    5 –32.10 (49.90) 5 –65.40 (58.20)
    9     0.08 (0.06) 7     0.04 (0.08)
  14  12
159  148
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Sitting balance/reach
Five trials (all RTT) recruiting 256 participants
measured sitting balance or functional reach
(Figure 4).66,68,70,76,77 Data were available for 82%
(n = 210). There was some heterogeneity of
treatment effects (I2 = 32%), although not
sufficient to merit the use of a random-effects
approach. 
The impact on sitting balance/reach showed a
small effect size that was not statistically significant
(SMD 0.23, 95% CI –0.05 to 0.50).
Upper limb function: follow-up
Under 6 months post-therapy
One CIMT trial measuring hand function84 and
two RTT trials measuring sitting balance,76,77
recruiting 78 participants in total, measured for
retention effects between post-therapy and 
under 6 months post-therapy (Figure 5). 
Data were available for 86% (n = 67) and 
effects across trials were homogeneous 
(I2 = 0%). There was a moderate effect size, 
which was statistically significant (SMD 0.55, 
95% CI 0.06 to 1.04). 
Between 6 and 12 months post-therapy
Four trials50,68,70,71 (all RTT) recruiting 254
participants measured arm function for retention
effects between 6 and 12 months post-therapy
(Figure 5). Data were available for 76% (n = 195).
Effects across trials were homogeneous (I2 = 0%).
Results showed no effect of treatment (SMD –0.02,
95% CI –0.31 to 0.26).
Subgroup analysis: upper limb 
function
Subgroup analyses for upper limb interventions
are based on trials providing measures of arm
function. Trials that only provide measures of
hand function84 or sitting balance/reach66,76,77 are
therefore excluded. Subgroup analyses are
presented for type, amount and timing of
intervention, and to consider the impact of
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 02 Upper limb function                                                                                        
Outcome: 03 Sitting balance/reach                                                                                  
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 RTT
de Sèze 200176   10       3.30 (0.80)         10        3.00 (0.80)       9.61   0.36 (–0.53 to 1.24)
Dean 199766   10     12.00 (0.95)           9      10.80 (0.90)       7.49   1.24 (0.23 to 2.24)
Howe 200577   15     –1.90 (0.80)         18      –2.10 (0.70)      15.89   0.26 (–0.43 to 0.95)
Langhammer 200068   29       5.40 (0.90)         24        5.00 (1.50)      25.38   0.33 (–0.22 to 0.87)
Van Vliet 200570   42       4.54 (1.49)         43        4.63 (1.42)      41.63 –0.06 (–0.49 to 0.36)
Subtotal (95% CI) 106                               104 100.00   0.23 (–0.05 to 0.50)
Test for heterogeneity: 2 = 5.88, df = 4 (p = 0.21), I2 = 32.0%
Test for overall effect: Z = 1.61 (p = 0.11)
Total (95% CI) 106                               104 100.00   0.23 (–0.05 to 0.50)
Test for heterogeneity: 2 = 5.88, df = 4 (p = 0.21), I2 = 32.0%
Test for overall effect: Z = 1.61 (p = 0.11)
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FIGURE 4 Sitting balance/reach
specific trial features on the results. The
classification of trials for each subgroup analysis is
given in Appendix 6. 
Type of intervention
Subgroups compared the treatment effects for
eight RTT trials recruiting 467 participants, and
seven CIMT trials recruiting 76 participants
(Figure 6). The impact of RTT on upper limb
function post-treatment just failed to reach
statistical significance (SMD 0.17, 95% CI –0.03 to
0.36). The impact of CIMT on arm function
showed some heterogeneity (I2 = 41%), but not
sufficient to necessitate the use of a random-effects
approach. There was a large and statistically
significant effect size (SMD 0.77, 95% CI 0.26 to
1.29). The difference between effect sizes for CIMT
and RTT was statistically significant (p = 0.03).
Results of the review
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 02 Upper limb function                                                                                        
Outcome: 04 Follow-up
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Under 6 months post-therapy
Boake, 200684         9        0.16 (0.06)         7        0.10 (0.10)       5.65   0.71 (–0.32 to 1.74)
de Sèze, 200176       10        3.60 (0.50)       10        3.40 (0.60)       7.62   0.35 (–0.54 to 1.23)
Howe, 200577       15        2.50 (1.30)       16        1.90 (0.50)      11.43   0.60 (–0.12 to 1.32)
Subtotal (95% CI)       34                                 33  24.70   0.55 (0.06 to 1.04)
Test for heterogeneity: 2 = 0.32, df = 2 (p = 0.85), I2 = 0%
Test for overall effect: Z = 2.19 (p = 0.03)
02 6–12 months post-therapy
Blennerhassett, 200450       10    –23.60 (12.20)      11    –31.00 (33.20)      8.04   0.28 (–0.58 to 1.14)
Langhammer, 200068       27        3.90 (2.50)       27         3.50 (2.80)      20.90   0.15 (–0.39 to 0.68)
Van Vliet, 200570       42        3.45 (2.40)       45         3.77 (2.37)      33.65 –0.13 (–0.55 to 0.29)
Winstein, 200471       17        9.67 (5.80)       16       10.98 (6.20)      12.72 –0.21 (–0.90 to 0.47)
Subtotal (95% CI)       96                          99  75.30 –0.02 (–0.31 to 0.26)
Test for heterogeneity: 2 = 1.42, df = 3 (p = 0.70), I2 = 0%
Test for overall effect: Z = 0.17 (p = 0.86)
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FIGURE 5 Arm function: follow-up at 0–6 months and more than 6 months post-therapy
Health Technology Assessment 2008; Vol. 12: No. 30
23
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 03 Subgroup analyses: upper limb                                                                              
Outcome: 01 Type of intervention                                                                                       
Study  Treatment  Control  SMD (fixed)  Weight SMD (fixed)
or subcategory N Mean (SD) N Mean (SD)  (95% CI) (%) (95% CI)
01 RTT
Blennerhassett, 200450     15        4.90 (1.90)         15       5.10 (1.50)       6.45 –0.11 (–0.83 to 0.60)
Higgins, 200652     47      29.00 (17.00)       44     28.00 (19.00)     19.58   0.06 (–0.36 to 0.47)
Kwakkel, 199953     27      20.00 (22.00)       34     10.00 (19.00)     12.59   0.48 (–0.03 to 1.00)
Langhammer, 200068     29        4.70 (2.00)         24       4.10 (2.30)      11.21   0.28 (–0.27 to 0.82)
Turton, 199069     12      13.83 (6.00)         10     12.25 (7.20)       4.66   0.23 (–0.61 to 1.07)
Van Vliet, 200570     42        3.88 (2.23)         43       3.69 (2.38)      18.30   0.08 (–0.34 to 0.51)
Winstein, 200471     20        9.58 (5.70)         20       9.47 (6.30)       8.62   0.02 (–0.60 to 0.64)
Yen, 200572     13      –2.57 (0.93)         17     –3.06 (1.54)       6.24   0.36 (–0.37 to 1.09)
Subtotal (95% CI)   205                                207  87.66   0.17 (–0.03 to 0.36)
Test for heterogeneity: 2 = 3.18, df = 7 (p = 0.87), I2 = 0%
Test for overall effect: Z = 1.67 (p = 0.09)
02 CIMT
Alberts, 200483       5    –28.89 (24.80)         5    –25.02 (17.96)      2.14 –0.16 (–1.40 to 1.08)
Atteya, 200479       2      52.00 (6.00)           2      51.50 (10.50)      0.85   0.03 (–1.94 to 2.00)
Dromerick, 200081     11     52.80 (5.90)            9      44.30 (11.10)      3.75   0.95 (0.01 to 1.89)
Page, 200180       2     53.00 (6.00)            2      51.00 (10.00)      0.74   0.14 (–1.97 to 2.25)
Page, 200582       5     49.80 (3.27)            5      35.80 (3.56)       0.56   3.70 (1.28 to 6.12)
Taub, 199373       4       8.10 (0.42)            5        6.90 (0.70)       1.13   1.79 (0.07 to 3.50)
Wittenberg, 200374       9       7.54 (2.04)            7        5.85 (2.79)       3.16   0.67 (–0.35 to 1.69)
Subtotal (95% CI)     38                                  35  12.34   0.77 (0.26 to 1.29)
Test for heterogeneity: 2 = 10.18, df = 6 (p = 0.12), I2 = 41.0%
Test for overall effect: Z = 2.93 (p = 0.003)
Total (95% CI)   243                                242 100.00   0.24 (0.06, 0.42)
Test for heterogeneity: 2 = 17.99, df = 14 (p = 0.21), I2 = 22.2%
Test for overall effect: Z = 2.59 (p = 0.010)
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FIGURE 6 Subgroup analysis: type of intervention – upper limb trials
Dosage of task practice
Seven trials (five RTT, two CIMT) with 399
participants provided up to 20 hours’ task
practice. Eight trials (three RTT, five CIMT) with
163 participants provided more than 20 hours’
task practice (Figure 7). There was substantial
heterogeneity (I2 = 50.8%) in the trials providing
up to 20 hours’ task practice, Using a random-
effects model to combine the effects from
individual trials, while the estimated effect 
was greater for the subgroup with more than 
20 hours of task practice, the difference between
subgroups failed to reach statistical significance
(p = 0.18). 
Results of the review
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Comparison: 03 Subgroup analyses: upper limb
Outcome: 02 Dosage of task practice
Study  Treatment  Control  SMD (random)  Weight  SMD (random)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 0–20 hours
Blennerhassett, 200450     15        4.90 (1.90)       15        5.10 (1.50)       7.47 –0.11 (–0.83 to 0.60)       
Dromerick, 200081      11      52.80 (5.90)         9      44.30 (11.10)      4.80   0.95 (0.01 to 1.89)        
Higgins, 200652      47      29.00 (17.00)     44      28.00 (19.00)     15.53   0.06 (–0.36 to 0.47)       
Langhammer, 200068      29        4.70 (2.00)       24        4.10 (2.30)      11.12   0.28 (–0.27 to 0.82)       
Page, 200582                  5      49.80 (3.27)         5      35.80 (3.56)       0.82   3.70 (1.28 to 6.12)        
Van Vliet, 200570           42        3.88 (2.23)       43        3.69 (2.38)      14.97   0.08 (–0.34 to 0.51)       
Winstein, 200471            20        9.58 (5.70)       20        9.47 (6.30)       9.28   0.02 (–0.60 to 0.64)       
Subtotal (95% CI)    169                              160  63.99   0.22 (–0.12 to 0.57)
Test for heterogeneity: 2 = 12.20, df = 6 (p = 0.06), I2 = 50.8%
Test for overall effect: Z = 1.27 (p = 0.20)
02 More than 20 hours
Alberts, 200483        5    –28.89 (24.80)       5    –25.02 (17.96)      2.92 –0.16 (–1.40 to 1.08)       
Atteya, 200479        2      52.00 (6.00)         2      51.50 (10.50)      1.23   0.03 (–1.94 to 2.00)       
Kwakkel, 199953      27      20.00 (22.00)     34      10.00 (19.00)     11.99   0.48 (–0.03 to 1.00)       
Page, 200180        2      53.00 (6.00)         2      51.00 (10.00)      1.08   0.14 (–1.97 to 2.25)       
Taub, 199373        4        8.10 (0.42)         5        6.90 (0.70)       1.60   1.79 (0.07 to 3.50)        
Turton, 199069      12      13.83 (6.00)       10      12.25 (7.20)       5.76   0.23 (–0.61 to 1.07)       
Wittenberg, 200374        9        7.54 (2.04)        7         5.85 (2.79)       4.14   0.67 (–0.35 to 1.69)       
Yen, 200572                 13      –2.57 (0.93)      17       –3.06 (1.54)       7.28   0.36 (–0.37 to 1.09)       
Subtotal (95% CI)      74                                82  36.01   0.42 (0.10 to 0.75)
Test for heterogeneity: 2 = 4.00, df = 7 (p = 0.78), I2 = 0%
Test for overall effect: Z = 2.56 (p = 0.01)
Total (95% CI)    243                              242 100.00   0.27 (0.05 to 0.49)
Test for heterogeneity: 2 = 17.99, df = 14 (p = 0.21), I2 = 22.2%
Test for overall effect: Z = 2.39 (p = 0.02)
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FIGURE 7 Subgroup analysis: dosage of task practice – upper limb trials
Time since stroke
Nine trials (four RTT, five CIMT) with 364
participants measured arm function in 
participants up to 6 months post-stroke. Six trials
(four RTT, two CIMT) with 189 participants
included participants more than 6 months 
post-stroke (Figure 8). There was some
heterogeneity in trials 0–6 months post-stroke 
(I2 = 34.8%), but not sufficient to warrant 
using a random-effects model. The difference
between subgroups did not reach statistical
significance (p = 0.65).
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 03 Subgroup analyses: upper limb                                                                              
Outcome: 03 Time since stroke                                                                                          
Study  Treatment  Control  SMD (fixed)  Weight SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 0–6 months
Alberts, 200483        5    –28.89 (24.80)        5    –25.02 (17.96)      2.14 –0.16 (–1.40 to 1.08)       
Atteya, 200479        2      52.00 (6.00)          2      51.50 (10.50)      0.85   0.03 (–1.94 to 2.00)       
Dromerick, 200081      11      52.80 (5.90)          9      44.30 (11.10)      3.75   0.95 (0.01 to 1.89)        
Kwakkel, 199953      27      20.00 (22.00)      34      10.00 (19.00)     12.59   0.48 (–0.03 to 1.00)       
Langhammer, 200068      29        4.70 (2.00)        24        4.10 (2.30)      11.21   0.28 (–0.27 to 0.82)       
Page, 200180        2      53.00 (6.00)          2      51.00 (10.00)      0.74   0.14 (–1.97 to 2.25)       
Page, 200582        5      49.80 (3.27)          5      35.80 (3.56)       0.56   3.70 (1.28 to 6.12)        
Van Vliet, 200570      42        3.88 (2.23)        43        3.69 (2.38)      18.30   0.08 (–0.34 to 0.51)       
Winstein, 200471      20        9.58 (5.70)        20        9.47 (6.30)       8.62   0.02 (–0.60 to 0.64)       
Subtotal (95% CI)    143                               144  58.77   0.28 (0.04 to 0.51)
Test for heterogeneity: 2 = 12.27, df = 8 (p = 0.14), I2 = 34.8%
Test for overall effect: Z = 2.28 (p = 0.02)
02 More than 6 months
Blennerhassett, 200450      15        4.90 (1.90)        15       5.10 (1.50)       6.45 –0.11 (–0.83 to 0.60)       
Higgins, 200652      47      29.00 (17.00)      44     28.00 (19.00)     19.58   0.06 (–0.36 to 0.47)       
Taub, 199373        4        8.10 (0.42)          5       6.90 (0.70)       1.13   1.79 (0.07 to 3.50)        
Turton, 199069      12      13.83 (6.00)        10     12.25 (7.20)       4.66   0.23 (–0.61 to 1.07)       
Wittenberg, 200374        9        7.54 (2.04)          7       5.85 (2.79)       3.16   0.67 (–0.35 to 1.69)       
Yen, 200572      13      –2.57 (0.93)        17     –3.06 (1.54)       6.24   0.36 (–0.37 to 1.09)       
Subtotal (95% CI)    100                                  98  41.23   0.19 (–0.09 to 0.47)
Test for heterogeneity: 2 = 5.51, df = 5 (p = 0.36), I2 = 9.2%
Test for overall effect: Z = 1.31 (p = 0.19)
Total (95% CI)    243                               242 100.00   0.24 (0.06 to 0.42)
Test for heterogeneity: 2 = 17.99, df = 14 (p = 0.21), I2 = 22.2%
Test for overall effect: Z = 2.59 (p = 0.010)
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FIGURE 8 Subgroup analysis: time since stroke – upper limb trials
Allocation concealment
Trials were grouped according to whether
allocation concealment was judged to be adequate
(five RTT trials) or inadequate/unclear (ten trials:
three RTT, seven CIMT) (Figure 9). There was
some heterogeneity observed in the
‘inadequate/unclear’ subgroup (I2 = 27.3%). 
The difference between subgroups was 
statistically significant (p = 0.08), indicating that
the effect of RFTP was greater for trials where
allocation concealment was either inadequate or
unclear.
Results of the review
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Comparison: 03 Subgroup analyses: upper limb                                                                              
Outcome: 04 Allocation concealment                                                                                     
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Adequate
Blennerhassett, 200450     15       4.90 (1.90)       15       5.10 (1.50)       6.45 –0.11 (–0.83 to 0.60)       
Higgins, 200652      47     29.00 (17.00)     44     28.00 (19.00)     19.58   0.06 (–0.36 to 0.47)       
Kwakkel, 199953      27     20.00 (22.00)     34     10.00 (19.00)     12.59   0.48 (–0.03 to 1.00)       
Van Vliet, 200570      42        3.88 (2.23)      43       3.69 (2.38)      18.30   0.08 (–0.34 to 0.51)       
Winstein, 200471      20        9.58 (5.70)      20       9.47 (6.30)       8.62   0.02 (–0.60 to 0.64)       
Subtotal (95% CI)    151                             156  65.55   0.12 (–0.10 to 0.35)
Test for heterogeneity: 2 = 2.58, df = 4 (p = 0.63), I2 = 0%
Test for overall effect: Z = 1.08 (p = 0.28)
02 Inadequate/unclear
Alberts, 200483        5    –28.89 (24.80)      5    –25.02 (17.96)      2.14 –0.16 (–1.40 to 1.08)       
Atteya, 200479        2      52.00 (6.00)        2      51.50 (10.50)      0.85   0.03 (–1.94 to 2.00)       
Dromerick, 200081      11      52.80 (5.90)        9      44.30 (11.10)      3.75   0.95 (0.01 to 1.89)        
Langhammer, 200068      29        4.70 (2.00)      24        4.10 (2.30)      11.21   0.28 (–0.27 to 0.82)       
Page, 200180        2      53.00 (6.00)        2      51.00 (10.00)      0.74   0.14 (–1.97 to 2.25)       
Page, 200582        5      49.80 (3.27)        5      35.80 (3.56)       0.56   3.70 (1.28 to 6.12)        
Taub, 199373        4        8.10 (0.42)        5        6.90 (0.70)       1.13   1.79 (0.07 to 3.50)        
Turton, 199069      12      13.83 (6.00)      10      12.25 (7.20)       4.66   0.23 (–0.61 to 1.07)       
Wittenberg, 200374        9        7.54 (2.04)        7        5.85 (2.79)       3.16   0.67 (–0.35 to 1.69)       
Yen, 200572      13      –2.57 (0.93)      17      –3.06 (1.54)       6.24   0.36 (–0.37 to 1.09)       
Subtotal (95% CI)      92                               86  34.45   0.46 (0.15 to 0.77)
Test for heterogeneity: 2 = 12.37, df = 9 (p = 0.19), I2 = 27.3%
Test for overall effect: Z = 2.93 (p = 0.003)
Total (95% CI)    243                             242 100.00   0.24 (0.06 to 0.42)
Test for heterogeneity: 2 = 17.99, df = 14 (p = 0.21), I2 = 22.2%
Test for overall effect: Z = 2.59 (p = 0.010)
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FIGURE 9 Subgroup analysis: allocation concealment – upper limb trials
Post hoc analysis: type of comparison group
Seven trials (five RTT, two CIMT) were 
classified as usual care or alternative treatment,
and eight trials (three RTT, five CIMT) were
classified as attention-control or no treatment
(Figure 10), with some heterogeneity observed 
in trials with usual care/alternative treatment
controls (I2 =46.1%). There was no statistically
significant difference between subgroups
(p = 0.84).
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 03 Subgroup analyses: upper limb
Outcome: 05 Comparison group
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Usual care/alternative treatment
Dromerick, 200081      11      52.80 (5.90)        9      44.30 (11.10)      3.75      0.95 (0.01 to 1.89)        
Langhammer, 200068      29        4.70 (2.00)      24        4.10 (2.30)      11.21      0.28 (–0.27 to 0.82)       
Page, 200582        5      49.80 (3.27)        5      35.80 (3.56)       0.56      3.70 (1.28 to 6.12)        
Turton, 199069      12      13.83 (6.00)      10      12.25 (7.20)       4.66      0.23 (–0.61 to 1.07)       
Van Vliet, 200570      42        3.88 (2.23)      43        3.69 (2.38)      18.30      0.08 (–0.34 to 0.51)       
Winstein, 200471      20        9.58 (5.70)      20        9.47 (6.30)       8.62      0.02 (–0.60 to 0.64)       
Yen, 200572      13      –2.57 (0.93)      17      –3.06 (1.54)       6.24      0.36 (–0.37 to 1.09)       
Subtotal (95% CI)    132                             128  53.35      0.26 (0.01 to 0.51)
Test for heterogeneity: 2 = 11.13, df = 6 (p = 0.08), I2 = 46.1%
Test for overall effect: Z = 2.02 (p = 0.04)
02 Attention control/no treatment
Alberts, 200483        5    –28.89 (24.80)      5    –25.02 (17.96)      2.14    –0.16 (–1.40 to 1.08)       
Atteya, 200479        2      52.00 (6.00)        2        1.50 (10.50)      0.85      0.03 (–1.94 to 2.00)       
Blennerhassett, 200450      15        4.90 (1.90)      15        5.10 (1.50)       6.45    –0.11 (–0.83 to 0.60)       
Higgins, 200652      47      29.00 (17.00)    44      28.00 (19.00)     19.58      0.06 (–0.36 to 0.47)       
Kwakkel, 199953      27      20.00 (22.00)    34      10.00 (19.00)     12.59      0.48 (–0.03 to 1.00)       
Page, 200180        2      53.00 (6.00)        2      51.00 (10.00)      0.74      0.14 (–1.97 to 2.25)       
Taub, 199373        4        8.10 (0.42)        5        6.90 (0.70)       1.13      1.79 (0.07 to 3.50)        
Wittenberg, 200374        9        7.54 (2.04)        7        5.85 (2.79)       3.16      0.67 (–0.35 to 1.69)       
Subtotal (95% CI)    111                             114  46.65      0.22 (–0.04 to 0.49)
Test for heterogeneity: 2 = 6.82, df = 7 (p = 0.45), I2 = 0%
Test for overall effect: Z = 1.63 (p = 0.10)
Total (95% CI)    243                             242 100.00     0.24 (0.06 to 0.42)
Test for heterogeneity: 2 = 17.99, df = 14 (p = 0.21), I2 = 22.2%
Test for overall effect: Z = 2.59 (p = 0.010)
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FIGURE 10 Subgroup analysis: type of comparison group – upper limb trials
Post hoc analysis: equivalence of therapy time
One subgroup comprised seven trials (two RTT,
five CIMT) which gave, additional therapy time to
the experimental group, and the other contained
eight trials (six RTT, two CIMT) where therapy
time for experimental and control groups was
equivalent (Figure 11). There was some
heterogeneity of treatment effects in each
subgroup, but not sufficient to merit the use of a
random-effects meta-analysis. There was no
significant difference between the two subgroups 
(p = 0.92).
Post hoc analysis: trial size 
The median number of participants in the trials
was 23. A post hoc analysis was therefore
undertaken for trials with under 25 participants
versus those with 25 or more participants
(Figure 12). Some heterogeneity was observed in
trials with under 25 participants (I2 = 38.2%), 
but not enough to warrant the use of a random-
effects model. The difference between effect sizes
in the small trial sub-group (<25 participants) and
the larger trial sub-group (25 participants) was
statistically significant (p = 0.06). As the effect in
the small trial subgroup (SMD 0.62, 95% CI 0.18
to 1.07) is significantly larger than in the larger
trial subgroup (SMD 0.16, 95% CI –0.04 to 0.36),
this may indicate some degree of reporting bias in
upper limb trials. This is supported by the funnel
plot in Figure 13, which has some apparent
asymmetry indicating a potential lack of 
reporting of small negative trials with large
standard errors.
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Comparison: 03 Subgroup analyses: upper limb
Outcome: 06 Equivalence of therapy time
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Additional therapy time
Alberts, 200483        5    –28.89 (24.80)     5    –25.02 (17.96)      2.14    –0.16 (–1.40 to 1.08)      
Atteya, 200479        2      52.00 (6.00)       2      51.50 (10.50)      0.85      0.03 (–1.94 to 2.00)      
Page, 200180        2      53.00 (6.00)       2      51.00 (10.00)      0.74      0.14 (–1.97 to 2.25)      
Page, 200582        5      49.80 (3.27)       5      35.80 (3.56)       0.56      3.70 (1.28 to 6.12)        
Turton, 199069      12      13.83 (6.00)     10      12.25 (7.20)       4.66      0.23 (–0.61 to 1.07)      
Winstein, 200471      20        9.58 (5.70)     20        9.47 (6.30)       8.62      0.02 (–0.60 to 0.64)      
Wittenberg, 200374        9        7.54 (2.04)       7        5.85 (2.79)       3.16      0.67 (–0.35 to 1.69)      
Subtotal (95% CI)      55                               51  20.76      0.25 (–0.15 to 0.65)
Test for heterogeneity: 2 = 9.44, df = 6 (p = 0.15), I2 = 36.5%
Test for overall effect: Z = 1.23 (p = 0.22)
02 Equivalent therapy time
Blennerhassett, 200450     15        4.90 (1.90)     15        5.10 (1.50)       6.45    –0.11 (–0.83 to 0.60)      
Dromerick, 200081      11      52.80 (5.90)       9      44.30 (11.10)      3.75      0.95 (0.01 to 1.89)        
Higgins, 200652      47      29.00 (17.00)   44      28.00 (19.00)     19.58      0.06 (–0.36 to 0.47)      
Kwakkel, 199953      27      20.00 (22.00)   34      10.00 (19.00)     12.59      0.48 (–0.03 to 1.00)      
Langhammer, 200068      29        4.70 (2.00)     24        4.10 (2.30)      11.21      0.28 (–0.27 to 0.82)      
Taub, 199373        4        8.10 (0.42)       5        6.90 (0.70)       1.13      1.79 (0.07 to 3.50)        
Van Vliet, 200570      42        3.88 (2.23)     43        3.69 (2.38)      18.30      0.08 (–0.34 to 0.51)      
Yen, 200572                13      –2.57 (0.93)     17      –3.06 (1.54)       6.24      0.36 (–0.37 to 1.09)      
Subtotal (95% CI)    188                             191  79.24      0.24 (0.03 to 0.44)
Test for heterogeneity: 2 = 8.54, df = 7 (p = 0.29), I2 = 18.0%
Test for overall effect: Z = 2.28 (p = 0.02)
Total (95% CI)    243                             242 100.00      0.24 (0.06 to 0.42)
Test for heterogeneity: 2 = 17.99, df = 14 (p = 0.21), I2 = 22.2%
Test for overall effect: Z = 2.59 (p = 0.010)
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FIGURE 11 Subgroup analysis: equivalence of therapy time – upper limb trials
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 03 Subgroup analyses: upper limb
Outcome: 07 Trial size
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Under 25 participants
Alberts, 200483               5   –28.89 (24.80)      5   –25.02 (17.96)      2.14   –0.16 (–1.40 to 1.08)       
Atteya, 200479        2     52.00 (6.00)        2     51.50 (10.50)      0.85     0.03 (–1.94 to 2.00)       
Dromerick, 200081      11     52.80 (5.90)        9     44.30 (11.10)      3.75     0.95 (0.01 to 1.89)        
Page, 200180        2     53.00 (6.00)        2     51.00 (10.00)      0.74     0.14 (–1.97 to 2.25)       
Page, 200582        5     49.80 (3.27)        5     35.80 (3.56)       0.56     3.70 (1.28 to 6.12)        
Taub, 199373        4       8.10 (0.42)        5       6.90 (0.70)       1.13     1.79 (0.07 to 3.50)        
Turton, 199069      12     13.83 (6.00)      10     12.25 (7.20)       4.66     0.23 (–0.61 to 1.07)       
Wittenberg, 200374        9       7.54 (2.04)        7       5.85 (2.79)       3.16     0.67 (–0.35 to 1.69)       
Subtotal (95% CI)      50                               45  17.01     0.62 (0.18 to 1.07)
Test for heterogeneity: 2 = 11.33, df = 7 (p = 0.12), I2 = 38.2%
Test for overall effect: Z = 2.77 (p = 0.006)
02 25 or more participants
Blennerhassett, 200450     15       4.90 (1.90)      15       5.10 (1.50)       6.45   –0.11 (–0.83 to 0.60)       
Higgins, 200652      47     29.00 (17.00)    44     28.00 (19.00)     19.58     0.06 (–0.36 to 0.47)       
Kwakkel, 199953      27     20.00 (22.00)    34     10.00 (19.00)     12.59     0.48 (–0.03 to 1.00)       
Langhammer, 200068      29       4.70 (2.00)      24       4.10 (2.30)      11.21     0.28 (–0.27 to 0.82)       
Van Vliet, 200570      42       3.88 (2.23)      43       3.69 (2.38)      18.30     0.08 (–0.34 to 0.51)       
Winstein, 200471      20       9.58 (5.70)      20       9.47 (6.30)       8.62     0.02 (–0.60 to 0.64)       
Yen, 200572      13     –2.57 (0.93)      17     –3.06 (1.54)       6.24     0.36 (–0.37 to 1.09)       
Subtotal (95% CI)    193                             197  82.99     0.16 (–0.04 to 0.36)
Test for heterogeneity: 2 = 3.15, df = 6 (p = 0.79), I2 = 0%
Test for overall effect: Z = 1.59 (p = 0.11)
Total (95% CI)    243                             242 100.00     0.24 (0.06 to 0.42)
Test for heterogeneity: 2 = 17.99, df = 14 (p = 0.21), I2 = 22.2%
Test for overall effect: Z = 2.59 (p = 0.010)
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FIGURE 12 Subgroup analysis: trial size – upper limb trials
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 03 Subgroup analyses: upper limb                                                                              
Outcome: 08 Trial size                                                                                                 
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FIGURE 13 Funnel plot of precision versus effect size – upper limb trials
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 04 Lower limb function
Outcome: 01 Walking distance
Study  Treatment  Control  WMD (random)  Weight  WMD (random)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 RTT
Blennerhassett, 200450     15   221.00 (65.40)     15   107.00 (85.60)      9.81   114.00 (59.49 to 168.52)     
Dean, 200067        5     42.03 (30.42)       4       4.76 (4.90)      20.79     37.27 (10.18 to 64.36)      
Salbach, 200451      44     40.00 (72.00)     47       5.00 (66.00)     20.04     35.00 (6.56 to 63.44)       
Subtotal (95% CI)      64                               66  50.65     54.59 (17.50 to 91.68)
Test for heterogeneity: 2 = 6.94, df = 2 (p = 0.03), I2 = 71.2%
Test for overall effect: Z = 2.88 (p = 0.004)
02 TM
Ada, 200387      11     99.00 (70.00)     14     13.00 (27.00)     13.09     86.00 (42.28 to 129.72)     
da Cunha, 200286        6   107.00 (71.52)       7     51.58 (63.00)      6.19     55.42 (–18.42 to 129.26)   
Eich, 200489      25     90.60 (43.50)     25     55.70 (32.60)     24.17     34.90 (13.59 to 56.21)      
Macko, 200588      25   281.03 (120.00)   20   264.57 (136.31)     5.90     16.46 (–59.58 to 92.50)     
Subtotal (95% CI)      67                                66  49.35     48.88 (19.56 to 78.20)
Test for heterogeneity: 2 = 4.84, df = 3 (p = 0.18), I2 = 38.0%
Test for overall effect: Z = 3.27 (p = 0.001)
Total (95% CI)    131                              132 100.00     50.05 (29.65 to 70.44)
Test for heterogeneity: 2 = 11.79, df = 6 (p = 0.07), I2 = 49.1%
Test for overall effect: Z = 4.81 (p < 0.00001)
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FIGURE 14 Walking distance
Lower limb function: post-therapy
Results are presented for walking distance, walking
speed, functional ambulation, sit-to-stand, lower
limb functional measures and standing
balance/reach. All results are post-therapy, except
for Langhammer and Stanghelle,68 which is
3 months post-stroke, and Van Vliet and
colleagues,70 which is 3 months post-baseline. 
Walking distance
Seven trials included a measure of walking
distance (Figure 14). All results are change from
baseline scores except for Macko and colleagues,88
and are expressed as metres walked in 6 minutes.
The degree of heterogeneity (I2 = 49.1%) in the
effect sizes of the seven trials was very close to the
study criterion for ‘substantial’ heterogeneity, so a
random-effects model was used. Three RTT
trials50,51,67 recruiting 133 participants measured
walking distance, with outcome data available for
98% (n = 130) of participants. Four TM trials86–89
recruiting 155 participants measured walking
distance, with outcome data available for 96%
(n = 149).
For RFTP overall, pooled results showed a
statistically significant difference (WMD 50.05 m,
95% CI 29.65 to 70.44 m). Owing to the lack of
homogeneity of standard deviations, resulting in a
substantial impact on the weighting of several
trials, results were reanalysed using the SMD and a
random-effects model. The result showed a large
effect size, which remained highly statistically
significant (SMD 0.98, 95% CI 0.58 to 1.39,
excluding Macko and colleagues,88 which did not
provide ‘change-from-baseline’ data). To improve
comparability with effect sizes for other outcomes
and for use in the economic analysis, the SMD
based on the post-treatment data from the seven
trials was also computed (SMD 0.45, 95% CI 0.20
to 0.70; figure not shown). As expected, the SMD
based on the post-treatment data is considerably
smaller than that based on the change-from-
baseline data, primarily owing to its poorer
sensitivity to change.
Walking speed
Ten trials included a measure of walking speed
(Figure 15). Results were converted into metres per
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 04 Lower limb function
Outcome: 02 Walking speed
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
02 RTT
Dean, 199766      10    –33.80 (18.60)      8    –29.40 (33.90)      4.19   –0.16 (–1.09 to 0.77)       
Dean, 200067        5        0.80 (0.43)        4        0.88 (0.52)       2.09   –0.15 (–1.47 to 1.17)       
Kwakkel, 199953      26        0.65 (0.46)      34        0.37 (0.41)      13.22     0.64 (0.12 to 1.16)        
Salbach, 200451      44        0.78 (0.40)      47        0.64 (0.37)      21.13     0.36 (–0.05 to 0.78)       
Van Vliet, 200570      42    –12.19 (9.05)      43    –11.75 (7.88)      20.08   –0.05 (–0.48 to 0.37)       
Subtotal (95% CI)    127                             136  60.70     0.23 (–0.01 to 0.48)
Test for heterogeneity: 2 = 5.40, df = 4 (p = 0.25), I2 = 25.9%
Test for overall effect: Z = 1.86 (p = 0.06)
03 TM
Ada, 200387      11        0.75 (0.26)      14        0.56 (0.30)       5.49     0.65 (–0.17 to 1.46)       
da Cunha, 200286       6        0.59 (0.29)        7        0.27 (0.23)       2.47     1.15 (–0.06 to 2.36)       
Eich, 200489      25        0.71 (0.30)      25        0.60 (0.22)      11.55     0.41 (–0.15 to 0.97)       
Macko, 200588      25        0.74 (0.30)      20        0.76 (0.36)      10.50   –0.06 (–0.65 to 0.53)       
Pohl, 200285      20        1.22 (0.74)      20        0.97 (0.64)       9.29     0.35 (–0.27 to 0.98)       
Subtotal (95% CI)      87                               86  39.30     0.35 (0.05 to 0.66)
Test for heterogeneity: 2 = 4.10, df = 4 (p = 0.39), I2 = 2.5%
Test for overall effect: Z = 2.27 (p = 0.02)
Total (95% CI)    214                             222 100.00     0.28 (0.09 to 0.47)
Test for heterogeneity: 2 = 9.86, df = 9 (p = 0.36), I2 = 8.7%
Test for overall effect: Z = 2.87 (p = 0.004)
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FIGURE 15 Walking speed
second, with the exception of Dean and
Shepherd66 and Van Vliet and colleagues,70 who
presented statistics for the number of 
seconds to walk 10 m and 6 m, respectively. There
was some heterogeneity of treatment effects 
(I2 = 8.7%), although not sufficient to merit the
use of a random-effects approach. Five RTT trials
recruited 311 participants,51,53,66,67,70 with
outcome data available for 85% (n = 263) 
of participants. Six TM trials recruited 229
participants.63,85–89 One TM trial with 30
participants provided data unsuitable for pooling,
with data for mean distance walked but no
standard deviations.63 Of the five remaining trials
with 199 participants, outcome data were available
for 87% (n = 173) of participants. 
Overall, pooled results for the impact of RFTP on
walking speed showed a small effect size, which
was statistically significant (SMD 0.28, 95% CI
0.09 to 0.47). A subgroup analysis was undertaken
for walking speed measured over short (5 or 6 m)
or medium (10 m) distances, with no significant
difference found (p = 0.57).
Functional ambulation
For RFTP overall, seven trials recruiting 368
participants measured functional ambulation, with
outcome data available for 79% (n = 291) (Figure 16).
Effects across trials were homogeneous (I2 = 0%).
Five RTT trials53,68,70,76,78 recruited 295 participants,
with outcome data available for 81% (n = 238). Two
TM trials85,86 recruited 59 participants, with outcome
data available for 89% (n = 53).
Pooling the results from seven trials showed RFTP
to have a statistically significant but small effect on
functional ambulation measures (SMD 0.28, 95%
CI 0.05 to 0.51), with no significant difference in
effects between RTT and TM (p = 0.66). 
Sit-to-stand
Seven trials (all RTT) recruiting 397 participants
included a measure of sit-to-stand,50,51,65,67,68,70,77
with outcome data available for 87% (n = 346)
(Figure 17). 
Effects across trials were homogeneous (I2 = 0%),
showing a small to moderate effect size, which was
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32 FIGURE 17 Sit-to-stand
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 04 Lower limb function
Outcome: 04 Sit-to-stand
Study Treatment
N
Control
N
(Estimate (fixed)
(95% CI)
Weight
(%)
Estimate (fixed)
(95% CI)or subcategory  Estimate (SE)
01 RTT
Barreca, 200465        25                23      0.8715 (0.2812)  14.80     0.87 (0.32 to 1.42)        
Blennerhassett, 200450        15                15      0.7000 (0.3775)   8.21     0.70 (–0.04 to 1.44)      
Dean, 200067                    5                  4      0.5700 (0.6900)   2.46     0.57 (–0.78 to 1.92)      
Howe, 200577                  15                15      0.2500 (0.3673)   8.67     0.25 (–0.47 to 0.97)      
Langhammer, 200068            29                24      0.3000 (0.2800)  14.92     0.30 (–0.25 to 0.85)      
Salbach, 200451               44                47      0.1600 (0.2091)  26.76     0.16 (–0.25 to 0.57)      
Van Vliet, 200570             42                43      0.3500 (0.2200)  24.18     0.35 (–0.08 to 0.78)      
Subtotal (95% CI)      175              171   100.00     0.39 (0.18 to 0.61)
Test for heterogeneity: 2 = 5.16, df = 6 (p = 0.52), I2 = 0%
Test for overall effect: Z = 3.65 (p = 0.0003)
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FIGURE 16 Functional ambulation
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 04 Lower limb function
Outcome: 03 Functional ambulation
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 RTT
de Sèze, 200176      10     2.60 (1.40)      10     1.60 (1.50)       6.62     0.66 (–0.25 to 1.57)       
Kwakkel, 199953      25     4.00 (1.00)      34     3.00 (2.00)      19.47     0.60 (0.07 to 1.12)        
Langhammer, 200068      29     4.00 (1.60)      24     3.80 (2.00)      18.54     0.11 (–0.43 to 0.65)       
McClellan, 200478      12     4.30 (1.20)        9     4.70 (1.00)       7.15   –0.34 (–1.21 to 0.53)       
Van Vliet, 200570      42     3.70 (1.62)      43     3.39 (1.93)      29.93     0.17 (–0.25 to 0.60)       
Subtotal (95% CI)    118                          120  81.71     0.25 (0.00 to 0.51)
Test for heterogeneity: 2 = 4.60, df = 4 (p = 0.33), I2 = 13.0%
Test for overall effect: Z = 1.93 (p = 0.05)
02 TM
da Cunha, 200286        6     7.93 (3.65)        7     7.07 (4.50)       4.54     0.19 (–0.90 to 1.29)       
Pohl, 200285      20     4.60 (0.60)      20     4.30 (0.70)      13.75     0.45 (–0.18 to 1.08)       
Subtotal (95% CI)      26                            27  18.29     0.39 (–0.16 to 0.93)
Test for heterogeneity: 2 = 0.16, df = 1 (p = 0.69), I2 = 0%
Test for overall effect: Z = 1.39 (p = 0.16)
Total (95% CI)    144                         147 100.00     0.28 (0.05 to 0.51)
Test for heterogeneity: 2 = 4.95, df = 6 (p = 0.55), I2 = 0%
Test for overall effect: Z = 2.34 (p = 0.02)
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statistically significant (standardised effect size
0.39, 95% CI 0.18 to 0.61).
Lower limb functional measures
Four trials (all RTT) recruiting 223 participants
included a measure of lower limb function,50,67,68,70
with outcome data available for 79% (n = 177)
(Figure 18). Effects across trials were homogeneous
(I2 = 0%).
Results overall showed a small effect size, which
was not statistically significant (SMD 0.20, 95% CI
–0.10 to 0.50).
Standing balance and reach
Three trials (all RTT) recruiting 137 participants
measured standing balance or functional
reach,51,76,78 with outcome data available for 96%
(n = 132) (Figure 19).
Effects across trials were homogeneous (I2 = 0%),
showing a small effect size, which was not 
statistically significant (SMD 0.29, 95% 
CI –0.06 to 0.63).
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FIGURE 18 Lower limb functional measures
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 04 Lower limb function
Outcome: 05 Lower limb functional measures
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 RTT
Blennerhassett, 200450     15    11.10 (5.00)       15       8.50 (4.60)      16.59     0.53 (–0.20 to 1.26)      
Dean, 200067       5      9.80 (4.00)         4       5.80 (4.30)       4.40     0.86 (–0.56 to 2.28)      
Langhammer, 200068     29    41.00 (18.00)     24     39.00 (21.00)     30.17     0.10 (–0.44 to 0.64)      
Van Vliet, 200570     42      5.62 (4.02)       43       5.24 (4.30)      48.83     0.09 (–0.34 to 0.52)      
Subtotal (95% CI)     91                              86 100.00     0.20 (–0.10 to 0.50)
Test for heterogeneity: 2 = 1.99, df = 3 (p = 0.58), I2 = 0%
Test for overall effect: Z = 1.32 (p = 0.19)
Total (95% CI)     91                              86 100.00     0.20 (–0.10 to 0.50)
Test for heterogeneity: 2 = 1.99, df = 3 (p = 0.58), I2 = 0%
Test for overall effect: Z = 1.32 (p = 0.19)
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FIGURE 19 Standing balance/reach
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 04 Lower limb function                                                                                        
Outcome: 06 Standing balance and reach
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 RTT
de Sèze, 200176     10      2.40 (1.60)      10      2.00 (0.80)      15.19     0.30 (–0.58 to 1.19)       
McClellan, 200478    12    21.90 (9.40)        9    17.80 (7.40)      15.36     0.46 (–0.42 to 1.33)       
Salbach, 200451     44    44.00 (11.00)    47    41.00 (13.00)     69.46     0.25 (–0.17 to 0.66)       
Subtotal (95% CI)      66                              66 100.00     0.29 (–0.06 to 0.63)
Test for heterogeneity: 2 = 0.18, df = 2 (p = 0.91), I2 = 0%
Test for overall effect: Z = 1.64 (p = 0.10)
Total (95% CI)      66                              66 100.00     0.29 (–0.06 to 0.63)
Test for heterogeneity: 2 = 0.18, df = 2 (p = 0.91), I2 = 0%
Test for overall effect: Z = 1.64 (p = 0.10)
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Lower limb: follow-up
Under 6 months post-therapy
Six trials (four RTT67,76–78 and two TM87,89)
recruiting 174 participants measured some aspect
of lower limb function for retention effects
between post-therapy and under 6 months 
post-therapy (Figure 20). Outcome data were
available for 90% (n = 155). Effects across 
trials were homogeneous (I2 = 0%). Results
showed a small to moderate effect size which was
statistically significant (SMD 0.37, 95% CI 0.05 
to 0.69).
Between 6 and 12 months post-therapy
Three RTT trials recruiting 211 participants
measured some aspect of lower limb function for
retention effects of RTT interventions between 6
and 12 months post-therapy (Figure 20).50,68,70
Outcome data were available for 80% (n = 170).
There was some degree of heterogeneity of
treatment effects (I2 = 49.1%), although not
sufficient to merit the use of a random-effects
approach (and the small effect size precludes the
need to perform a sensitivity analysis on the choice
of analytic approach). Results showed no treatment
effect (SMD –0.01, 95% CI –0.32 to 0.29).
Subgroup analyses: lower limb 
function
Subgroup analyses for lower limb interventions 
are based on trials providing measures of walking
function (walking distance, walking speed or
functional ambulation rating). Trials that only
provide measures of standing balance/reach76 or
sit-to-stand65,77 are therefore excluded. Subgroup
analyses are presented for type, amount and
timing of intervention, and to consider the 
impact of adequacy of allocation concealment 
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 04 Lower limb function                                                                                        
Outcome: 07 Follow-up                                                                                                  
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Under 6 months post-therapy
Ada, 200387     13         0.83 (0.26)        13        0.64 (0.29)       7.70     0.67 (–0.13 to 1.46)       
de Sèze, 200176     10         3.10 (1.20)        10        2.50 (1.20)       6.09     0.48 (–0.41 to 1.37)       
Dean, 200067       4       84.00 (46.70)        4      81.50 (47.20)      2.52     0.05 (–1.34 to 1.43)       
Eich, 200489     24         0.77 (0.35)        25        0.58 (0.22)      14.64     0.64 (0.07 to 1.22)        
Howe, 200577     14       –4.20 (7.30)        15      –2.90 (2.50)       9.07   –0.24 (–0.97 to 0.50)       
McClellan, 200478     13       20.20 (9.40)        10      17.70 (8.40)       7.06     0.27 (–0.56 to 1.10)       
Subtotal (95% CI)     78                                  77  47.08     0.37 (0.05 to 0.69)
Test for heterogeneity: 2 = 4.36, df = 5 (p = 0.50), I2 = 0%
Test for overall effect: Z = 2.25 (p = 0.02)
02 6–12 months post-therapy
Blennerhassett, 200450      15    416.00 (171.00)    14    313.00 (154.00)     8.67     0.61 (–0.13 to 1.36)       
Langhammer, 200068      27        3.10 (2.30)        27        3.00 (2.30)      17.04     0.04 (–0.49 to 0.58)       
Van Vliet, 200570      42        3.24 (1.96)        45        3.70 (1.72)      27.21   –0.25 (–0.67 to 0.17)       
Subtotal (95% CI) 84 86  52.92   –0.01 (–0.32 to 0.29)
Test for heterogeneity: 2 = 3.93, df = 2 (p = 0.14), I2 = 49.1%
Test for overall effect: Z = 0.08 (p = 0.93)
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FIGURE 20 Lower limb follow-up at 0–6 months and more than 6 months post-therapy
and type of comparison group. There were
insufficient trials providing additional therapy
time or trials of fewer than 25 participants to
undertake subgroup analyses. The classification 
of trials for each subgroup analysis is given in
Appendix 6. 
Type of intervention
Twelve trials (seven RTT, five TM) included a
measure of walking ability (Figure 21). There was
some heterogeneity of treatment effects within
each subgroup, but not sufficient to merit the use
of random-effects analysis.
There was no statistically significant difference
between RTT and TM interventions (p = 0.62).
Dosage of task practice
Nine trials (five RTT, four TM) provided up to
20 hours’ training time and three trials (two RTT,
one TM) provided more than 20 hours’ training
time (Figure 22). There was substantial
heterogeneity in the more than 20 hours’ practice
subgroup (I2 = 59.4%), so a random-effects model
was used. There was no statistically significant
difference between subgroups (p = 0.65).
Time since stroke
Six trials (three RTT, three TM) recruited
0–6 months post-stroke and six trials (four RTT,
two TM) recruited more than 6 months post-stroke
(Figure 23). There was some heterogeneity of
treatment effects in both subgroups, but not
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 05 Subgroup analyses – lower limb                                                                             
Outcome: 01 Type of intervention                                                                                       
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 RTT
Blennerhassett, 200450      15   404.00 (101.00)    15    288.00 (124.00)     5.20     1.00 (0.23 to 1.76)        
Dean, 200067        5     80.20 (42.80)        4      88.40 (52.20)      1.75   –0.15 (–1.47 to 1.16)       
Kwakkel, 199953      26       0.65 (0.46)        34        0.37 (0.41)      11.09     0.64 (0.12 to 1.16)        
Langhammer, 200068      29       4.00 (1.60)        24        3.80 (2.00)      10.40     0.11 (–0.43 to 0.65)       
McClellan, 200478      12       4.30 (1.20)          9        4.70 (1.00)       4.01   –0.34 (–1.21 to 0.53)       
Salbach, 200451      44       0.78 (0.40)        47        0.64 (0.37)      17.72     0.36 (–0.05 to 0.78)       
Van Vliet, 200570      42   –12.19 (9.05)        43    –11.75 (7.88)      16.85   –0.05 (–0.48 to 0.37)       
Subtotal (95% CI)    173                              176  67.03     0.26 (0.05 to 0.47)
Test for heterogeneity: 2 = 10.38, df = 6 (p = 0.11), I2 = 42.2%
Test for overall effect: Z = 2.37 (p = 0.02)
02 TM
Ada, 200387      11       0.75 (0.26)        14       0.56 (0.30)       4.60     0.65 (–0.17 to 1.46)       
da Cunha, 200286        6       0.59 (0.29)          7       0.27 (0.23)       2.07     1.15 (–0.06 to 2.36)       
Eich, 200489      25       0.71 (0.30)        25       0.60 (0.22)       9.69     0.41 (–0.15 to 0.97)       
Macko, 200588      25       0.74 (0.30)        20       0.76 (0.36)       8.81   –0.06 (–0.65 to 0.53)       
Pohl, 200285      20       1.22 (0.74)        20       0.97 (0.64)       7.80     0.35 (–0.27 to 0.98)       
Subtotal (95% CI)      87                                 86  32.97     0.35 (0.05 to 0.66)
Test for heterogeneity: 2 = 4.10, df = 4 (p = 0.39), I2 = 2.5%
Test for overall effect: Z = 2.27 (p = 0.02)
Total (95% CI)    260                         262 100.00     0.29 (0.11, 0.46)
Test for heterogeneity: 2 = 14.73, df = 11 (p = 0.20), I2 = 25.3%
Test for overall effect: Z = 3.25 (p = 0.001)
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FIGURE 21 Subgroup analysis: type of intervention – lower limb trials
sufficient to merit a random-effects analysis. There
was no significant difference between subgroups
(p = 1.0).
Allocation concealment
Trials were grouped according to whether
allocation concealment was judged adequate 
(eight trials: six RTT, two TM) or inadequate/
unclear (four trials: one RTT, three TM) (Figure
24). There was heterogeneity within each
subgroup, but insufficient to warrant using a
random-effects meta-analysis. There was no
statistically significant difference between
subgroups (p = 0.51).
Post hoc analysis: type of comparison group
Six trials (two RTT, four TM) were classified as
usual care or alternative treatment, and six trials
(five RTT, one TM) as attention-control or no
treatment (Figure 25). There was some
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 05 Subgroup analyses – lower limb                                                                             
Outcome: 02 Dosage of task practice                                                                                    
Study  Treatment  Control  SMD (random)  Weight  SMD (random)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 0–20 hours
Ada, 200387      11        0.75 (0.26)         14        0.56 (0.30)       5.58     0.65 (–0.17 to 1.46)       
Blennerhassett, 200450      15    404.00 (101.00)     15    288.00 (124.00)     6.18     1.00 (0.23 to 1.76)        
da Cunha, 200286        6        0.59 (0.29)           7        0.27 (0.23)       2.76     1.15 (–0.06 to 2.36)       
Dean, 200067        5      80.20 (42.80)         4      88.40 (52.20)      2.36   –0.15 (–1.47 to 1.16)       
Eich, 200489      25        0.71 (0.30)         25        0.60 (0.22)       9.97     0.41 (–0.15 to 0.97)       
Langhammer, 200068      29        4.00 (1.60)         24        3.80 (2.00)      10.47     0.11 (–0.43 to 0.65)       
Pohl, 200285      20        1.22 (0.74)         20        0.97 (0.64)       8.50     0.35 (–0.27 to 0.98)       
Salbach, 200451      44        0.78 (0.40)         47        0.64 (0.37)      14.70     0.36 (–0.05 to 0.78)       
Van Vliet, 200570      42    –12.19 (9.05)         43    –11.75 (7.88)      14.27   –0.05 (–0.48 to 0.37)       
Subtotal (95% CI)    197                                199  74.79     0.33 (0.10 to 0.56)
Test for heterogeneity: 2 = 9.59, df = 8 (p = 0.29), I2 = 16.6%
Test for overall effect: Z = 2.85 (p = 0.004)
02 More than 20 hours
Kwakkel, 199953     26         0.65 (0.46)         34        0.37 (0.41)      10.95     0.64 (0.12 to 1.16)        
Macko, 200588     25         0.74 (0.30)         20        0.76 (0.36)       9.30   –0.06 (–0.65 to 0.53)       
McClellan, 200478     12         4.30 (1.20)           9        4.70 (1.00)       4.96   –0.34 (–1.21 to 0.53)       
Subtotal (95% CI)     63                                   63  25.21     0.14 (–0.44 to 0.73)
Test for heterogeneity: 2 = 4.93, df = 2 (p = 0.09), I2 = 59.4%
Test for overall effect: Z = 0.47 (p = 0.63)
Total (95% CI)    260                                262 100.00     0.30 (0.09 to 0.51)
Test for heterogeneity: 2 = 14.73, df = 11 (p = 0.20), I2 = 25.3%
Test for overall effect: Z = 2.82 (p = 0.005)
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FIGURE 22 Subgroup analysis: dosage of task practice – lower limb trials
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heterogeneity within each subgroup, but
insufficient to warrant the use of a random-effects
meta-analysis. The difference between subgroups
was marginally non-significant (p = 0.10), with the
estimated effect somewhat larger for the attention-
control/no treatment subgroup.
Trial size
No trials of lower limb interventions had fewer
than 25 participants, so subgroup analysis was not
undertaken. The funnel plot in Figure 26 does not
suggest reporting bias.
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 05 Subgroup analyses – lower limb
Outcome: 03 Time since stroke
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 0–6 months
da Cunha, 200286        6       0.59 (0.29)         7       0.27 (0.23)       2.07     1.15 (–0.06 to 2.36)       
Eich, 200489      25       0.71 (0.30)       25       0.60 (0.22)       9.69     0.41 (–0.15 to 0.97)       
Kwakkel, 199953      26       0.65 (0.46)       34       0.37 (0.41)      11.09     0.64 (0.12 to 1.16)        
Langhammer, 200068      29       4.00 (1.60)       24       3.80 (2.00)      10.40     0.11 (–0.43 to 0.65)       
Pohl, 200285      20       1.22 (0.74)       20       0.97 (0.64)       7.80     0.35 (–0.27 to 0.98)       
Van Vliet, 200570      42   –12.19 (9.05)       43   –11.75 (7.88)      16.85   –0.05 (–0.48 to 0.37)       
Subtotal (95% CI)    148                             153  57.90     0.29 (0.06 to 0.51)
Test for heterogeneity: 2 = 6.76, df = 5 (p = 0.24), I2 = 26.0%
Test for overall effect: Z = 2.44 (p = 0.01)
02 More than 6 months
Ada, 200387      11       0.75 (0.26)       14       0.56 (0.30)       4.60     0.65 (–0.17 to 1.46)       
Blennerhassett, 200450      15   404.00 (101.00)   15   288.00 (124.00)     5.20     1.00 (0.23 to 1.76)        
Dean, 200067        5     80.20 (42.80)       4     88.40 (52.20)      1.75   –0.15 (–1.47 to 1.16)       
Macko, 200588      25       0.74 (0.30)       20       0.76 (0.36)       8.81   –0.06 (–0.65 to 0.53)       
McClellan, 200478      12       4.30 (1.20)         9       4.70 (1.00)       4.01   –0.34 (–1.21 to 0.53)       
Salbach, 200451      44       0.78 (0.40)       47       0.64 (0.37)      17.72     0.36 (–0.05 to 0.78)       
Subtotal (95% CI)    112                             109  42.10     0.29 (0.03 to 0.56)
Test for heterogeneity: 2 = 7.97, df = 5 (p = 0.16), I2 = 37.2%
Test for overall effect: Z = 2.15 (p = 0.03)
Total (95% CI)    260                             262 100.00     0.29 (0.11 to 0.46)
Test for heterogeneity: 2 = 14.73, df = 11 (p = 0.20), I2 = 25.3%
Test for overall effect: Z = 3.25 (p = 0.001)
–4 –2 0 2 4
 Favours control  Favours treatment
FIGURE 23 Subgroup analysis: time since stroke – lower limb trials
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FIGURE 24 Subgroup analysis: allocation concealment – lower limb trials
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 05 Subgroup analyses - lower limb
Outcome: 04 Allocation concealment
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Adequate
Ada, 200387      11       0.75 (0.26)        14       0.56 (0.30)       4.60     0.65 (–0.17 to 1.46)       
Blennerhassett, 200450      15   404.00 (101.00)    15   288.00 (124.00)     5.20     1.00 (0.23 to 1.76)        
Dean, 200067        5     80.20 (42.80)        4     88.40 (52.20)      1.75   –0.15 (–1.47 to 1.16)       
Eich, 200489      25       0.71 (0.30)        25       0.60 (0.22)       9.69     0.41 (–0.15 to 0.97)       
Kwakkel, 199953      26       0.65 (0.46)        34       0.37 (0.41)      11.09     0.64 (0.12 to 1.16)        
McClellan, 200478      12       4.30 (1.20)          9       4.70 (1.00)       4.01   –0.34 (–1.21 to 0.53)       
Salbach, 200451      44       0.78 (0.40)        47       0.64 (0.37)      17.72     0.36 (–0.05 to 0.78)       
Van Vliet, 200570      42   –12.19 (9.05)        43   –11.75 (7.88)      16.85   –0.05 (–0.48 to 0.37)       
Subtotal (95% CI)    180                               191  70.92     0.33 (0.12 to 0.53)
Test for heterogeneity: 2 = 10.85, df = 7 (p = 0.15), I2 = 35.5%
Test for overall effect: Z = 3.09 (p = 0.002)
02 Inadequate/unclear
da Cunha, 200286        6       0.59 (0.29)          7       0.27 (0.23)       2.07     1.15 (–0.06, 2.36)       
Langhammer, 200068      29       4.00 (1.60)        24       3.80 (2.00)      10.40     0.11 (–0.43, 0.65)       
Macko, 200588      25       0.74 (0.30)        20       0.76 (0.36)       8.81   –0.06 (–0.65, 0.53)       
Pohl, 200285      20       1.22 (0.74)        20       0.97 (0.64)       7.80     0.35 (–0.27, 0.98)       
Subtotal (95% CI)      80                                71  29.08     0.20 (–0.13, 0.52)
Test for heterogeneity: 2 = 3.45, df = 3 (p = 0.33), I2 = 13.0%
Test for overall effect: Z = 1.20 (p = 0.23)
Total (95% CI)    260                              262 100.00     0.29 (0.11 to 0.46)
Test for heterogeneity: 2 = 14.73, df = 11 (p = 0.20), I2 = 25.3%
Test for overall effect: Z = 3.25 (p = 0.001)
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 05 Subgroup analyses – lower limb
Outcome: 05 Comparison group
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Usual care/alternative treatment
da Cunha, 200286        6       0.59 (0.29)          7       0.27 (0.23)       2.07     1.15 (–0.06 to 2.36)       
Eich, 200489      25       0.71 (0.30)        25       0.60 (0.22)       9.69     0.41 (–0.15 to 0.97)       
Langhammer, 200068      29       4.00 (1.60)        24       3.80 (2.00)      10.40     0.11 (–0.43 to 0.65)       
Macko, 200588      25       0.74 (0.30)        20       0.76 (0.36)       8.81   –0.06 (–0.65 to 0.53)       
Pohl, 200285      20       1.22 (0.74)        20       0.97 (0.64)       7.80     0.35 (–0.27 to 0.98)       
Van Vliet, 200570      42   –12.19 (9.05)        43   –11.75 (7.88)      16.85   –0.05 (–0.48 to 0.37)       
Subtotal (95% CI)    147                              139  55.62     0.16 (–0.07 to 0.39)
Test for heterogeneity: 2 = 5.22, df = 5 (p = 0.39), I2 = 4.3%
Test for overall effect: Z = 1.34 (p = 0.18)
02 Attention control/no treatment
Ada, 200387      11       0.75 (0.26)        14       0.56 (0.30)       4.60     0.65 (–0.17 to 1.46)       
Blennerhassett, 200450      15   404.00 (101.00)    15   288.00 (124.00)     5.20     1.00 (0.23 to 1.76)        
Dean, 200067        5     80.20 (42.80)        4     88.40 (52.20)      1.75   –0.15 (–1.47 to 1.16)       
Kwakkel, 199953      26       0.65 (0.46)        34       0.37 (0.41)      11.09     0.64 (0.12 to 1.16)        
McClellan, 200478      12       4.30 (1.20)          9       4.70 (1.00)       4.01   –0.34 (–1.21 to 0.53)       
Salbach, 200451      44       0.78 (0.40)        47       0.64 (0.37)      17.72     0.36 (–0.05 to 0.78)       
Subtotal (95% CI)    113                              123  44.38     0.45 (0.19 to 0.71)
Test for heterogeneity: 2 = 6.86, df = 5 (p = 0.23), I2 = 27.1%
Test for overall effect: Z = 3.37 (p = 0.0007)
Total (95% CI)    260                              262 100.00     0.29 (0.11 to 0.46)
Test for heterogeneity: 2 = 14.73, df = 11 (p = 0.20), I2 = 25.3%
Test for overall effect: Z = 3.25 (p = 0.001)
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FIGURE 25 Subgroup analysis: type of comparison group – lower limb trials
Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 05 Subgroup analyses – lower limb
Outcome: 06 Trial size
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FIGURE 26 Funnel plot of precision versus effect size – lower limb trials
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 06 Global motor function
Outcome: 01 Global motor function scales
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 RTT
Langhammer, 200068     29    37.00 (12.00)    24    33.00 (15.00)     29.14     0.29 (–0.25 to, 0.84)       
Van Vliet, 200570     42      7.85 (3.17)      43      6.69 (3.52)      46.96     0.34 (–0.09 to 0.77)       
Subtotal (95% CI)     71                             67  76.10     0.32 (–0.01 to 0.66)
Test for heterogeneity: 2 = 0.02, df = 1 (p = 0.89), I2 = 0%
Test for overall effect: Z = 1.89 (p = 0.06)
02 TM
Macko, 200588     25      12.00 (0.30)    20    11.80 (0.40)      23.90     0.57 (–0.04 to 1.17)       
Subtotal (95% CI)     25                             20  23.90     0.57 (–0.04 to 1.17)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.84 (p = 0.07)
Total (95% CI)     96                             87 100.00     0.38 (0.09 to 0.68)
Test for heterogeneity: 2 = 0.49, df = 2 (p = 0.78), I2 = 0%
Test for overall effect: Z = 2.55 (p = 0.01)
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FIGURE 27 Global motor function
Global motor function
Two RTT trials68,70 recruiting 181 participants
measured global motor function (Figure 27).
Outcome data were available for 76% (n = 138).
Three TM trials63,88,89 recruiting 105 participants
measured global motor function. Data were not
suitable for pooling from two trials.63,89 Standard
deviations were not given for one trial.63 One
trial89 showed no significant difference in RMA
score for gross functions, but provided median
and IQR scores only: experimental group median
11 (IQR 11–11), control group median 11 (IQR
10–11).
The trials with outcome data suitable for pooling
showed a small to moderate effect size which was
statistically significant (SMD 0.38, 95% CI 0.09 
to 0.68).
Overall summary analysis
The primary analysis requires an overall estimate
of the effect of RFTP on functional outcome
(Figure 28). To gain an overall measure of 
RFTP as a preliminary basis for the economic
analysis, a summary plot was constructed, with
subcategories for the different intervention 
types. Some RTT trials included both upper 
and lower limb intervention–control pairs. To
avoid their being included twice, the lower limb
intervention–control group was chosen, as it is
known that lower limb treatment effects are more
likely. By privileging lower limb outcomes, this
would have the effect of providing a slightly
inflated overall effect size.
Twenty-six intervention–control pairs with 876
participants provided data suitable for pooling,
with outcome data available for 88% (n = 775).
Figure 28 shows that the overall treatment effect of
RFTP (with selection of lower limb functional
outcomes in studies with multiple
intervention–control pairs, or in studies with both
upper and lower limb intervention) was small to
moderate and statistically significant (SMD 0.34,
95% CI 0.19 to 0.48).
If selection is based on upper limb functional
outcomes from trials with multiple
intervention–control pairs, or in studies with both
upper and lower limb intervention, the results are
small and statistically significant (SMD 0.26, 95%
CI 0.12 to 0.41), indicating that the findings are
not particularly sensitive to the choice of lower
limb rather than upper limb outcomes.
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 07 Summary analysis RFTP
Outcome: 01 Functional outcomes (inc. lower limb)
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD) (95% CI) (%) (95% CI)
01 Upper limb RTT
Turton, 199069      12     13.83 (6.00)          10   12.25 (7.20)       2.95     0.23 (–0.61 to 1.07)       
Winstein, 200471      20       9.58 (5.70)          20     9.47 (6.30)       5.45     0.02 (–0.60 to 0.64)       
Yen, 200572      13     –2.57 (0.93)          17   –3.06 (1.54)       3.94     0.36 (–0.37 to 1.09)       
Subtotal (95% CI)      45                          47  12.33     0.18 (–0.23 to 0.59)
Test for heterogeneity: 2 = 0.52, df = 2 (p = 0.77), I2 = 0%
Test for overall effect: Z = 0.85 (p = 0.39)
02 Upper limb CIMT
Alberts, 200483        5   –28.89 (24.80)        5   –25.02 (17.96)      1.35   –0.16 (–1.40 to 1.08)       
Atteya, 200479        2     52.00 (6.00)          2     51.50 (10.50)      0.54     0.03 (–1.94 to 2.00)       
Boake, 200684        9       0.08 (0.06)          7       0.04 (0.08)       2.04     0.55 (–0.47 to 1.56)       
Dromerick, 200081      11     52.80 (5.90)          9     44.30 (11.10)      2.37     0.95 (0.01 to 1.89)        
Page, 200180        2     53.00 (6.00)          2     51.00 (10.00)      0.47     0.14 (–1.97 to 2.25)       
Page, 200582        5     49.80 (3.27)          5     35.80 (3.56)       0.36     3.70 (1.28 to 6.12)        
Taub, 199373        4       8.10 (0.42)          5       6.90 (0.70)       0.71     1.79 (0.07 to 3.50)        
Wittenberg, 200374        9       7.54 (2.04)          7       5.85 (2.79)       2.00     0.67 (–0.35 to 1.69)       
Subtotal (95% CI)      47                                42   9.84     0.73 (0.27 to 1.19)
Test for heterogeneity: 2 = 10.33, df = 7 (p = 0.17), I2 = 32.2%
Test for overall effect: Z = 3.09 (p = 0.002)
03 Lower limb RTT
Blennerhassett, 200450      15   404.00 (101.00)    15   288.00 (124.00)     3.57     1.00 (0.23 to 1.76)        
Dean, 200067        5     80.20 (42.80)        4     88.40 (52.20)      1.20   –0.15 (–1.47 to 1.16)       
Kwakkel, 199953      26       0.65 (0.46)        34       0.37 (0.41)       7.62     0.64 (0.12 to 1.16)        
Langhammer, 200068      29       4.00 (1.60)        24       3.80 (2.00)       7.14     0.11 (–0.43 to 0.65)       
McClellan, 200478      12       4.30 (1.20)          9       4.70 (1.00)       2.75   –0.34 (–1.21 to 0.53)       
Salbach, 200451      44       0.78 (0.40)        47       0.64 (0.37)      12.17     0.36 (–0.05 to 0.78)       
Van Vliet, 200570      42   –12.19 (9.05)        43   –11.75 (7.88)      11.57   –0.05 (–0.48 to 0.37)       
Subtotal (95% CI)    173                              176  46.02     0.26 (0.05 to 0.47)
Test for heterogeneity: 2 = 10.38, df = 6 (p = 0.11), I2 = 42.2%
Test for overall effect: Z = 2.37 (p = 0.02)
04 Lower limb TM
Ada, 200387      11       0.75 (0.26)        14       0.56 (0.30)       3.16     0.65 (–0.17 to 1.46)       
da Cunha, 200286        6       0.59 (0.29)          7       0.27 (0.23)       1.42     1.15 (–0.06 to 2.36)       
Eich, 200489      25       0.71 (0.30)        25       0.60 (0.22)       6.65     0.41 (–0.15 to 0.97)       
Macko, 200588      25       0.74 (0.30)        20       0.76 (0.36)       6.05   –0.06 (–0.65 to 0.53)       
Pohl, 200285      20       1.22 (0.74)        20       0.97 (0.64)        5.35     0.35 (–0.27 to 0.98)       
Subtotal (95% CI)      87                                86  22.64     0.35 (0.05 to 0.66)
Test for heterogeneity: 2 = 4.10, df = 4 (p = 0.39), I2 = 2.5%
Test for overall effect: Z = 2.27 (p = 0.02)
05 Sitting and standing balance RTT
de Sèze, 200176      10       3.30 (0.80)        10       3.00 (0.80)       2.67     0.36 (–0.53 to 1.24)       
Dean, 199766      10     12.00 (0.95)          9     10.80 (0.90)       2.08     1.24 (0.23 to 2.24)        
Howe, 200577      15     –1.90 (0.80)        18     –2.10 (0.70)       4.41     0.26 (–0.43 to 0.95)       
Subtotal (95% CI)      35                                37   9.16     0.51 (0.03 to 0.99)
Test for heterogeneity: 2 = 2.63, df = 2 (p = 0.27), I2 = 23.9%
Test for overall effect: Z = 2.10 (p = 0.04)
Total (95% CI)    387                              388 100.00     0.34 (0.19 to 0.48)
Test for heterogeneity: 2 = 32.31, df = 25 (p = 0.15), I2 = 22.6%
Test for overall effect: Z = 4.59 (p < 0.00001)
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FIGURE 28 Overall impact of all forms of RFTP on functional outcome
Secondary outcomes
ADL function
Five RTT trials with seven intervention–control
pairs51,53,68,70,76 and recruiting a total of 399
people used a measure of ADL, with data available
for 81% (n = 325) (Figure 29). One CIMT trial81
recruiting 23 participants used a measure of ADL,
with data available for 87% (n = 20). No TM trials
included ADL data. For RFTP overall, six trials
recruiting 422 participants included a measure of
ADL, with outcome data available for 82%
(n = 345).
Results showed a small statistically significant
effect size (SMD 0.30, 95% CI 0.09 to 0.52).
Adverse effects
One RTT trial of sit-to-stand training65 presented
data for the number of falls: intervention 
group 3/25 (12%) versus control group 4/23
(17.4%), (odds ratio 0.65, 95% CI 0.13 to 3.27).
No other trials presented data for adverse 
events, but two trials narratively reported no
adverse effects.76,78 In one trial,51 intervention-
related reasons for withdrawal that could be
interpreted as adverse events included one person
out of 47 in a mobility-training group who
experienced the onset of groin pain. Four
participants also fell during the mobility
intervention, but did not suffer injury and
continued to participate in the group. Two falls
also occurred during evaluation. No other trials
reported intervention-related reasons for
withdrawal.
Eight CIMT trials did not mention adverse
events,61,62,64,74,79,80,82,83 although four of these
trials stated that participants were highly satisfied
with the protocol.61,79,80,82 A further two trials
stated there were no adverse events,81,84 with one
trial author commenting further that there was no
Results of the review
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Review: Repetitive functional task practice (including RTT, CIMT, TM)
Comparison: 08 Secondary outcomes
Outcome: 01 ADL function
Study  Treatment  Control  SMD (fixed)  Weight  SMD (fixed)
or subcategory N Mean (SD) N Mean (SD)  95% CI (%) (95% CI)
01 RTT
de Sèze, 200176      10     99.40 (10.80)      10   101.70 (14.30)      5.98   –0.17 (–1.05 to 0.70)       
Kwakkel, 199953      54     16.96 (3.66)        34     14.00 (5.00)      23.67     0.69 (0.25 to 1.14)        
Langhammer, 200068     29     83.00 (25.00)      24     72.00 (34.00)     15.51     0.37 (–0.18 to 0.91)       
Salbach, 200451      40     93.40 (18.70)      39     90.20 (12.60)     23.62     0.20 (–0.24 to 0.64)       
Van Vliet, 200570      42     16.02 (3.90)        43     15.78 (4.40)      25.53     0.06 (–0.37 to 0.48)       
Subtotal (95% CI)    175                              150  94.31     0.29 (0.07 to 0.51)
Test for heterogeneity: 2 = 5.69, df = 4 (p = 0.22), I2 = 29.7%
Test for overall effect: Z = 2.56 (p = 0.01)
02 TM
Subtotal (95% CI)        0                                  0         Not estimable
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 CIMT
Dromerick, 200081      11   100.00 (1.10)         9     98.50 (3.77)       5.69     0.54 (–0.36 to 1.44)       
Subtotal (95% CI)      11                                  9   5.69     0.54 (–0.36 to 1.44)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.18 (p = 0.24)
Total (95% CI)    186                             159 100.00     0.30 ( 0.09 to 0.52)
Test for heterogeneity: 2 = 5.98, df = 5 (p = 0.31), I2 = 16.3%
Test for overall effect: Z = 2.77 (p = 0.006)
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FIGURE 29 ADL function
evidence of excess disability associated with
CIMT.81 In one trial, the first three participants to
receive restraint reported stiffness and discomfort
on the involved side half-way through the 2-week
treatment period.73 These effects were associated
with overuse of the affected limb and led to
modification of the intervention protocol for the
fourth participant, with motor demands increasing
more slowly. The fourth participant reported no
muscle soreness. There were no intervention-
related reasons for withdrawal in any CIMT or
mCIMT trial. Of the six TM trials, three reported
that there were no adverse events.85,87,89 There are
no reports of adverse events in three trials.63,86,88
None of the trials reported intervention-related
reasons for withdrawal that could be interpreted as
adverse events. 
Sensitivity analysis
A sensitivity analysis was undertaken to evaluate
the effect on upper limb outcomes of including
cross-over and quasi-randomised trials,63,69 finding
no substantive difference between including (SMD
0.24, 95% CI 0.06 to 0.42) and not including
(SMD 0.24, 95% CI 0.05 to 0.43) these trials. A
sensitivity analysis was also undertaken on lower
limb trials to evaluate the effect of excluding
studies with more than 20% loss to follow-up (only
one upper limb trial had loss to follow-up of
greater than 20%). The effect of RFTP was
significantly greater (p = 0.02) for trials with loss
to follow-up of 20% or less (SMD 0.42, 95% CI
0.22 to 0.63) than for trials with more than 
20% loss to follow-up (SMD –0.06, 95% CI –0.39 
to 0.27). 
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Background
The systematic review identified studies that will
potentially alter patient outcomes by using RTT.
There were three forms of therapy that had RTT
as a major component: RTT, CIMT, and TM. The
therapies will subsequently be referred to as RFTP.
The economic modelling reported below was
designed to determine whether RFTP is cost-
effective. 
Study question
From the perspective of the NHS, is RFTP for
stroke (in addition to usual care) cost-effective over
3 years as judged by the incremental cost per
quality-adjusted life-year (QALY) gained?
Perspective
The analyses performed took the perspective of
the NHS and Personal Social Services (PSS). The
cost of stroke tends to be higher in the acute stage
owing to the inpatient cost. Once a patient is
discharged from hospital, some of the costs will be
borne by the NHS through provision of therapy
and aids, and some will be borne by PSS through
provision of support services. RFTP would take
place after the acute stage of treatment and hence
will have no effect on these costs; therefore they
are not considered in this analysis. 
Current treatment
At present, the amount of physical therapy input
to post-stroke patients varies widely. In hospital,
most patients receive physiotherapy and
occupational therapy. Once their care is transferred
into the community, the provision of therapies is
much less structured. This means that it is difficult
to define a standard package of physical therapy
after stroke. For this analysis usual care was based
on observations of a cohort of patients treated in
the NHS over time with the amount of physical
therapy varying between patients. For the cost
analysis the alternative treatments compared here
are usual care and usual care plus RFTP.
Methods
Form of evaluation
A cost–utility approach was adopted, assessing
gains in QALYs. The authors believe this to be the
most meaningful outcome measure on which to
base the economic evaluation. The nature of RFTP
means that it will not directly prevent death,
excluding a cost-effectiveness analysis of life-years
gained. An alternative would be to express the
effects of RFTP in terms of a change in units of
some measure of function; however, the authors
believe that this would be generally less
meaningful than identifying a cost per QALY
gained. The modelling is based over a 3-year
period.
Choice of RFTP intervention
The economic analysis is based around the three
forms of therapy described in the systematic
review: RTT, CIMT and TM.
Measures of benefit
The health outcome summary measure is the
number of QALYs gained. A health outcome was
needed that could be used across the three forms
of therapy described. 
The patient data set
The patient data set used for the modelling is a
longitudinal data set that contains follow-up data
for a cohort of 539 stroke patients, consecutively
identified over a 6-month period in 1996, on
stroke registers in two hospitals.134 Data were
collected on admission, at discharge, and at 3 and
6 months, and subsequently 1, 2, and 3 years post-
stroke. The data collected in hospital included
admission and discharge dates, basic
demographics, stroke characteristics and scan
results. At each follow-up time patient status (alive
or dead) was identified, and data were collected
regarding residence, function, social service input,
therapy input and aids provided. These patients
received usual stroke care and their 3-year data
were used as the baseline from which to judge the
potential impact of RFTP. The baseline
characteristics of these patients can be seen in
Appendix 7. The characteristics of the data set
compare favourably with the characteristics of the
patients in the included studies.
Assumptions about health outcomes
The Barthel Activities of Daily Living Index (BI)135
at 3 years post-stroke was used to define outcome
groups, which represented a range of disability
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levels, and such that there were similar numbers in
each group. The choice of the BI was based on its
widespread usage as a global outcome in stroke
research and because it had been mapped onto
the EuroQol-5 Dimensions (EQ-5D).136 The BI is a
ten-item scale ranging from 0 (dependent on
others for ADLs) to 20 (independent of others for
ADLs); the items measured include mobility,
transfers, grooming and feeding. The number of
patients in each Barthel category was 28 
(BI  10); 34 (BI = 11–14); 33 (BI = 15–17), 25
(BI = 18 or 19) and 30 (BI = 20).
Efficacy of RFTP
A range of different outcome measures was used in
the systematic review. For each outcome the
effectiveness of RFTP was expressed as the SMD
with associated 95% CI. The exception to this was
for walking distance, which was expressed as WMD.
However, for the economic analysis, the SMD will
be used. In the economic analysis the focus was on
those outcomes that showed a significant benefit of
RFTP and where there were at least 250 patients in
the analysis of efficacy, because the estimates based
on such a sample size would be more robust.
However, walking speed was not included in the
economic analysis because it was felt that walking
distance was the more meaningful of these two
outcomes. To determine the potential impact of
RFTP, it was necessary to estimate how a change in
the SMD would equate to a change on the BI. It
was estimated that a change in the SMD of 0.2 was
equivalent to a change in 1 point on the BI. This
was based on the following assumption: SMD =
(treatment mean – control mean)/SD; a ‘typical SD’
for the BI in a rehabilitation stroke population
might be 5 units; therefore, an SMD of 0.2 would
be 1 Barthel unit.
Patient values preferences
A study was identified that examined the
association between the BI and the EQ-5D.136
Although this study was based in The
Netherlands, the characteristics of the patients
included in the study are similar to the
characteristics of those in the present patient data
set (at 6 months). The study136 suggested that 1
point on the BI was equivalent to 0.05 of a QALY.
Cost
The cost estimates reflect 2005/06 prices. Direct
costs have been used, valued from an NHS public-
sector perspective. The majority of the costs were
obtained from national figures.137 The exception to
this was the cost for aids, which were obtained from
an NHS loan store. The assumptions made about
the costs for the RFTP studies are detailed below.
Assumptions about costing
Patient data set
The analysis focused on the costs that were likely
to be influenced by RFTP, which included the cost
of services, therapy and aids post-discharge. Costs
were estimated from the following inputs: home
care, meals on wheels, chiropody, physiotherapy,
occupational therapy, day centre, day hospital,
wheelchair, walking frame, walking stick, toilet seat
raiser, chair raiser, bed raiser, toilet frame, trolley
and shopping trolley. The costs that were not
included were GP attendance, readmission to
hospital, clinic attendance or medication. Also
excluded were hospital costs for the index stroke
and subsequent hotel costs for residence in
institutions. Although RFTP is likely to promote
independence in everyday activities, it is unlikely
that it would prevent admission to institutions.
Moreover, there was some concern that high hotel
costs of institutions, or even readmissions to
hospital, would unduly influence the model and
the authors wished to adopt a conservative
approach to the estimates of cost-effectiveness.
RFTP studies
The RFTP studies included in the review exhibited
some diversity in when and where they were
performed; some were more than 10 years old and
many were not based in the UK. To estimate the
costs of such studies, an assumption was made that
they could be performed in a similar manner in
the UK. In addition, although the studies reported
on how much therapy was provided, there were no
data on the impact of the training on subsequent
resource use. Therefore, it was assumed that the
RFTP training did not result in additional costs
owing to readmission or clinic attendance, caused
by patients’ conditions worsening. 
Because of the diverse nature of studies and the
data reported therein, a somewhat pragmatic
approach to costing methodology was taken. It was
assumed that for all studies the therapy staff cost
was £40 per hour and that as well as the cost of
providing the therapy there would be an
additional 20 hours of staff training per study. The
lack of CIMT data from the UK meant that an
estimate of the cost of CIMT equipment had to be
made, of £100 per patient. The TM studies used a
cost of £25,000 for the equipment plus an
additional £1500 for installation. Within the RTT
studies there were miscellaneous costs for which
the following cost estimates were made: Bon Saint
Côme trunk control and retraining device £1000,
videotaped instructions and telephone contacts
£500, and instruction booklets £600. In one
study67 a Kinetron machine was used in one
Economic analysis
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workstation out of ten. The original cost of this
machine was approximately £32,000. Because 
this device is no longer manufactured and it
contributed only a small part to the RTT input, 
a cost of £1000 was attributed to this device. For
all equipment the one-off cost of purchase was
used and no assumptions were made about the
lifetime of the equipment or how often it was
used.
For each trial an average cost per patient was
calculated based on staff time, equipment used
and number of patients randomised into the
trial. Subsequently, an average cost per therapy
(i.e. RTT, CIMT and TM) was calculated based
on the average cost for each trial and the
number of trials that contributed to that therapy
modality. From this calculation the estimated
average cost per patient for the individual
therapies was £651 for RTT, £1773 for CIMT
and £1870 for TM. Further estimates were then
made of the average cost per patient for
combinations of therapy. To make the calculation
for combinations of therapy, an average cost for
all trials in the relevant therapy modalities was
estimated. This resulted in an average cost per
patient of £1126 for RTT and CIMT combined,
and £999 for RTT and TM combined. The
overall average cost per person of RFTP (i.e.
RTT, CIMT and TM combined) for the base
model was estimated to be £1265.
Where outcome measures reflected all forms of
therapy (overall effect), the cost of the
intervention was taken from the overall average
cost of RFTP. Where outcome measures reflected
therapy focusing on the upper limb (arm function
and ADL), the cost of the intervention was taken
from the average cost of RTT and CIMT. Where
outcome measures reflected therapy focusing on
the lower limb (walking distance, functional
ambulation and sit-to-stand), the cost of the
intervention was taken from the average cost of
RTT and TM.
The model
Groups were identified, based on the BI at 3 years
as described above. For each group the 3-year cost
was estimated: the baseline cost in this analysis. It
was then assumed that for an SMD of 0.2, there
would be a 1-point increase per patient on the BI,
that the BI scores were evenly distributed within
the groups and that the effect would be
maintained over 3 years. Using this assumption,
the number of patients in each of the Barthel
groups was re-estimated. A new (3-year) cost was
then calculated based on the new numbers in each
of the groups. The difference between the baseline
cost and the new cost was considered to represent
the impact of RFTP on cost. An average cost per
patient, reflecting the potential cost saving of
RFTP, was subsequently calculated, as £47,523/150
= £316.82 (Appendix 8).
Adjustment for timing of costs and benefits
For the base model the cost–utility of RFTP over
3 years was assessed, and costs and effects were
discounted at an annual rate of 3.5%.
Allowances for uncertainty
Several sensitivity analyses were performed to
explore the impact of varying certain parameters
on the base model:
● RFTP efficacy
● association between the SMD and the BI
● association between the BI and the EQ-5D
● cost of therapy
● discount rates.
The relationship between the cost of RFTP 
per patient and the cost per QALY was also
explored.
Results
From the systematic review, the overall effect size
for RFTP was SMD 0.34 (95% CI 0.19 to 0.48).
The following outcomes were based on studies
where the combined sample size was more than
250 patients, and revealed a significant effect of
RFTP.
● arm function: SMD 0.24 (95% CI 0.06 to 0.42)
● ADL: SMD 0.30 (95% CI 0.09 to 0.52)
● walking distance: SMD 0.45 (95% CI 0.20 to
0.70)
● functional ambulation: SMD 0.28 (95% CI 0.05
to 0.51)
● sit-to-stand: SMD 0.39 (95% CI 0.18 to 0.61).
The effect sizes for the five outcomes are based on
RTT plus one of either CIMT or TM. For arm
function there was heterogeneity of effect between
RTT, which was non significant (SMD 0.17, 95%
CI –0.03 to 0.36) and CIMT, which was significant
(SMD 0.77, 95% CI 0.26 to 1.29). However, the
estimates of cost-effectiveness will use the
combined effect size.
Cost-effectiveness at 3 years
In the base-case analysis using the overall effect
size, the incremental cost-effectiveness ratio
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(ICER) of RFTP was £10,870. Considering the
efficacy and cost data for the outcome of arm
function, the cost per QALY gained was £15,185
and when focusing on the efficacy and cost data
for ADLs the cost per QALY gained was £11,009.
Based on efficacy and cost data for walking
distance the cost per QALY gained was £4187, and
for functional ambulation and sit-to-stand the cost
per QALY gained was £10,187 and £5708,
respectively. An intervention with an ICER of less
than £20,000 is considered cost-effective138
(although interventions with an ICER of up to
£30,000 may be considered cost-effective).
Therefore, for all outcomes listed, the base
analysis suggests that RFTP is cost-effective.
Moreover, for walking distance and sit-to-stand,
when the ICER was calculated using the lower
limit of effectiveness from the 95% CI, both of the
ICER values were less than £20,000 (Appendix 9;
Analysis 1).
Varying the association between the
SMD and the BI
If a unit change of the SMD was related to a
smaller change on the BI, the cost per QALY
gained increases for all outcome measures. In the
base case the ratio of SMD to BI is 1:5. Even if this
ratio is changed to 1:4, the ICER remains below
£20,000 per QALY gained for all outcomes except
for arm function (£20,405). Sit-to-stand remains
cost-effective at a ratio of 1:3 and walking distance
remains cost-effective at a ratio of 1:2 
(Appendix 9; Analysis 2).
Varying the association between the BI
and the EQ-5D
If a unit change on the BI is associated with a
smaller change in the EQ-5D the ICER increases
for all outcome measures. If a change in 1 point
on the BI is equivalent to only 0.04 of a QALY, all
outcomes continue to suggest that RFTP is cost
effective (Appendix 9; Analysis 3).
Varying therapy cost
RFTP remains cost-effective on all outcomes
except for arm function if the cost of therapy per
hour is increased to £60. However, RFTP is
marginally cost-effective for arm function if the
cost of therapy rises to £50 per hour (Appendix 9;
Analysis 4).
Varying discount rate (cost)
If the discount rate for costs is reduced from 3.5%
to 0% then the ICER is reduced to £10,228 for the
overall outcome and, for example, £3545 for
walking distance and £14,543 for arm function. If
the discount rate for cost is increased from 3.5% to
6%, RFTP is cost-effective on all outcomes
(Appendix 9; Analysis 5).
Varying discount rate (outcome)
If outcome is not discounted then the ICER is
reduced to £9191 for the overall outcome and, for
example, £3186 for walking distance and £13,068
for arm function. Even if the discount rate is
increased to 6%, RFTP is cost-effective on all
outcomes (Appendix 9; Analysis 6).
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FIGURE 30 Impact of varying the cost of RFTP on the cost per QALY gained
Association between cost of RFTP and
cost per QALY gained
The base costs were used to calculate how a
change in the cost of RFTP per patient affects the
ICER per QALY gained. At an ICER of £20,000
per QALY gained the average cost of RFTP per
patient is £1963, which approximates to 49 hours’
contact per patient, excluding equipment costs
(Figure 30).
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Summary of main results
Upper limb function/sitting balance
In total, 19 RFTP trials with 634 participants
measured arm or hand function. Eight were 
RTT trials with 467 participants. Of these, two
trials were whole therapy approaches,68,70
two trials were circuit-training approaches,50,52
three trials were functional task practice mixed 
in with other forms of upper limb exercise,53,69,71
and one trial was the intensive practice
component of constraint-induced movement
therapy, without the constraint.72 All of these
interventions were delivered by a therapist, except
for one trial, which consisted of self-initiated
practice in the home environment, using a booklet
of exercises, after instruction by a therapist.69 Of
the upper limb training trials, all but two52,72 were
carried out 0–6 months post-stroke. Five trials had
a total training time of 20 hours or less,50,52,68,70,71
and three trials provided more than 20 hours’
total training time.53,69,72 In two of the trials
training time was additional.69,71 All eight 
trials with eight intervention–control pairs 
relevant to this review provided data suitable 
for pooling. 
Eleven of the 19 trials measuring arm or hand
function were CIMT trials with 190 participants.
Of these, five trials were of constraint-induced
therapy,64,73,74,83,84 and six trials were of modified
constraint-induced therapy.61,62,79–81,139 All of the
interventions were delivered by a therapist, in one-
to-one therapy. Three trials recruited within
14 days post-stroke,81,82,84 four trials recruited
between 15 days and 6 months post-
stroke,61,79,80,83 and four trials recruited after more
than 6 months post-stroke.64,73,74,139 All but two
trials81,82 had a total training time of over
20 hours, with the majority providing between 30
and 60 hours’ training. In four trials, training time
was additional to the amount of training time
provided to the comparison group,74,79,80,82 while
in one trial it was unclear whether training time
between experimental and comparison groups was
equivalent.73 Eight CIMT trials including 151
participants in eight intervention–control pairs
relevant to this review provided data suitable for
pooling. Pooled results show evidence of a small
effect (SMD 0.24, 95% CI 0.06 to 0.42).
Seven RFTP trials with 357 participants measured
hand function. There was no statistically
significant pooled effect (SMD 0.19, 95% CI –0.03
to 0.42). 
Five trials (all RTT) with 256 participants
measured sitting balance/reach from
sitting.66,68,70,76,77 Of these, two trials were whole
therapy approaches,68,70 while the other three
trials specifically trained sitting balance or reach
from sitting. All of the interventions were carried
out in the 0–6-month post-stroke period and were
delivered by a therapist in a hospital setting,
except for one trial where the intervention was
carried out at home, with people more than 6
months post-stroke.66 All of the interventions were
20 hours’ training or less. There was no evidence
for impact on sitting balance/reach (SMD 0.23,
95% CI –0.05 to 0.50).
Results at follow-up for all upper limb trials to
6 months post-therapy were moderate and
statistically significant (SMD 0.55, 95% CI 0.06 to
1.04). Evidence for a retention effect at more than
6 months post-therapy was unclear (SMD –0.02 to
95% CI –0.31 to 0.26), as it was noted that the
trials with 6–12-month follow-up also showed little
or no effect post-treatment.
Treatment effects for upper limb interventions
were not modified by amount/dosage of task
practice or time since stroke, but were modified by
type of intervention, with RTT showing a small
effect size just failing to reach significance (SMD
0.17, 95% CI –0.03 to 0.36), and CIMT showing a
large, statistically significant effect (SMD 0.77,
95% CI 0.26 to 1.29). However, tests for the effect
of quality of allocation concealment and trial size
were also significant, with all of the CIMT trials in
both the inadequate/unclear allocation
concealment subgroup and the small trials
subgroup. This suggests that the results for CIMT
trials could be influenced by quality issues and
reporting bias.
Lower limb function/standing balance
Seventeen RFTP trials with 747 participants
measured some aspect of lower limb function or
standing balance/reach. Eleven were RTT trials
with 531 participants. Of these, one trial
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specifically trained sit-to-stand movements,65 three
trials trained balance,66,76,77 two trials were whole
therapy approaches,68,70 three trials were circuit-
training approaches,50,51,67 and two trials were
lower limb task practice mixed in with other forms
of mobility exercise.53,78 All interventions were
delivered by a therapist in a hospital or
community setting, except for one trial, which was
a home mobility programme, where the
participant followed videotaped exercise with
therapist telephone contact and follow-up.78 Three
of the interventions were carried out more than
6 months post-stroke.51,67,78 Two trials included
more than 20 hours’ total practice time.53,78 All 11
trials had data suitable for pooling. Six of the 17
trials were TM trials with 229 participants. Of
these, two trials were of unsupported TM87,88 and
four trials were of bodyweight supported
TM.63,85,86,89 All interventions were delivered by a
therapist in a hospital setting. Two interventions
were carried out more than 6 months post-
stroke.87,88 Only one of the trials included more
than 20 hours’ training time.88 Five trials with 199
participants provided data suitable for pooling. 
Results show large statistically significant effects
for walking distance (WMD 50.05 m, 95% CI
29.65 to 70.44 m; SMD 0.98, 95% CI 0.58 to
1.39). In effect, participants in the experimental
groups could walk on average 50 m further in
6 minutes than the control groups. However, there
was some heterogeneity of treatment effects for
walking distance. There were also small statistically
significant effects for walking speed (SMD 0.28,
95% CI 0.09 to 0.47) and functional ambulation
(SMD 0.28, 95% CI 0.05 to 0.51). Trials of RTT
showed a small to moderate effect on sit-to-stand
(standardised effect size 0.39, 95% CI 0.18 to
0.61), but no evidence of effect on lower limb
function measures (SMD 0.20, 95% CI –0.10 to
0.50) or standing balance/reach (SMD 0.29, 95%
CI, –0.06 to 0.63). 
Retention effects on lower limbs were small to
moderate and statistically significant up to
6 months post-therapy (SMD 0.37, 95% CI 0.05 to
0.69), but there was no evidence of an effect at
later than 6 months (SMD –0.01, 95% CI –0.32 to
0.29). This difference in retention effects was
borderline statistically significant (p = 0.09).
However, few trials had long follow-up and those
that did tended to show little or no effect post-
treatment. Findings are also quite heterogeneous,
which suggests that they are inconclusive. 
Treatment effects were not modified by amount of
task practice, time since stroke or type of
intervention. Tests for the effect of quality of
allocation concealment were not statistically
significant. However, trials with high (>20%) loss
to follow-up showed a significantly lower effect of
RFTP than did trials with lower (20%) loss. This
is an indication that any bias due to very high
dropout is not in favour of RTT, although it would
be important in future trials to try to characterise
dropouts and attempt to determine their effect on
the effectiveness of RFTP. There was some
indication that treatment effects might be
modified by type of comparison group (p = 0.10),
with usual care or alternative treatment
comparisons showing a smaller treatment effect
than attention-control or no-treatment
comparisons. This suggests that type of
comparison group should be taken into
consideration in future analyses.
Global motor function
Two RTT trials68,70 and one TM trial with data
suitable for pooling88 recruiting 242 participants
in total measured global motor function. Data
were available for 76% (n = 183). There was a
pooled small to moderate, statistically significant
effect (SMD 0.38, 95% CI 0.09 to 0.68).
ADL function
Five RTT trials and one CIMT trial recruiting a
total of 422 participants used an ADL measure.
Outcome data were available for 83% (n = 345).
Overall results indicated a small effect size that
was statistically significant (SMD 0.30, 95% CI
0.09 to 0.52).
Adverse events
Ten out of the 31 trials included some report of
adverse events. Of these, seven reported no
adverse events. One RTT trial reported a number
of falls occurring during the intervention or
evaluation, none of which was serious,51 and one
CIMT trial reported that three participants had
some discomfort in the unaffected limb, attributed
to overuse during the constraint period.73 The
protocol was subsequently modified. The only trial
formally to measure adverse events did not show
any significant difference in fall rates between the
intervention and control groups.65
Overall completeness and
applicability of evidence
The included trials were clinically diverse in terms
of timing and focus, and there are gaps in the
evidence base, particularly for people more than
6 months post-stroke. Of the five trials that
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evaluated more than 20 hours’ therapy for upper
limbs in this participant group, only three had
usable data.72–74 Only one trial evaluated 20 hours
or less of upper limb therapy in people at least
6 months post-stroke.52
There were only three trials that evaluated up to
20 hours of lower limb therapy in people more
than 6 months post-stroke,51,67,87 and two trials
evaluating more than 20 hours of lower limb
therapy in this group.78,88
There have been more trials undertaken with
people in the 0–6-month post-stroke period, but
here there are also gaps in the evidence base. Of
the seven trials evaluating upper limb therapy of
more than 20 hours’ duration, one had data
unsuitable for pooling. Of the remaining six, one
was quasi-experimental, and three had ten
participants or fewer. While 11 trials have
evaluated 20 hours or less of lower limb therapy,
only one trial has evaluated more than 20 hours of
lower limb therapy in the 0–6-month post-stroke
period. 
Although it was not possible to classify studies into
more disabled or less disabled participant
subgroups, the tables of included studies
(Appendixes 1–3) illustrate the wide range of
disability levels of the participants in the included
trials. However, many of the trials had inclusion
criteria specifying either minimum, or minimum
and maximum levels of ability, motivation to
participate and ability to understand instruction.
The general evidence provided by the review
therefore appears to be widely applicable, perhaps
with the exception of very severely disabled people
with little postural control or voluntary movement,
those with very mild deficits and those with severe
communication difficulties who were excluded by
trialists. The exception to the above may be in
CIMT studies, which identified criteria for
minimum levels of finger and wrist extension.
Treatment effects for CIMT may only be
applicable to a subgroup of participants with a
degree of voluntary movement in the hand or
arm. There is also the possibility that exclusion
criteria for maximum residual ability reduce
generalisability. The preliminary phase of a CIMT
trial reported that less than 5% of stroke
admissions qualified for randomisation.84
Trials were excluded where repetition appeared to
be primarily for strength or endurance training
(e.g. cycling and gait training), or where the type
of training appeared divorced from the functional
aim (e.g. backward walking training, slot machines
and computer games). This may have
consequences for the applicability of the evidence.
The exclusion of trials of what could be defined as
‘prefunctional’ types of movement will effectively
have excluded a group of people who cannot yet
participate in functional movement. The same
consequence applies to the exclusion of trials with
a large element of passive and active assisted
movement.
In terms of generalisability to the UK, only RTT-
type interventions have been evaluated in this
setting. One trial is a whole therapy approach,70
one trial evaluates balance training77 and one
quasi-experimental trial evaluated self-delivered
exercise in the home environment.69 RTT has not
traditionally been a significant part of therapy after
stroke in the UK, which has been dominated by
the Bobath approach. This specifically minimises
repetitive active movement, and relies on
therapist-guided restoration of ‘normal movement’
patterns, rather than the functional but unnatural
ones that could occur as a result of the more
pragmatic approach within RFTP. Many studies in
this review were from outside the UK, or used
therapy approaches that have been less popular,
such as motor learning. While clinical experience
suggests that modern UK stroke units have a more
eclectic therapy approach, it may take longer for
the results to change practice within the UK than
in countries that already use RFTP routinely. 
There are no published trials of either CIMT or
TM in a UK setting. While all of the interventions
are likely to be transferable in principle, their
effectiveness against other forms of care usual in
the UK and their acceptability in this healthcare
setting have not been tested. In particular, the
feasibility and acceptability of CIMT and circuit-
training interventions delivered in community
settings would need to be evaluated. The intensity
of CIMT and the delivery of interventions after
the normal rehabilitation period represent
additional periods of treatment to those currently
provided. 
The acceptability and safety of the different forms
of RFTP to all types of participants are also
unclear. While there were few adverse effects
reported overall, the lack of formal reporting in
many trials means that this finding is inconclusive.
Of the information provided about reasons for
dropouts in the trials, the most frequent cause was
physical illness, and only a very small proportion
of those participating dropped out for physical
reasons that might have been related to the
intervention. However, there was also a small
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number of participants who were lost to follow-up
for reasons related to compliance or treatment
preference. In the CIMT trials in particular,
relatively long periods of constraint and intensive
periods of practice with the affected limb have the
potential to impact on acceptability, although
none of the trials reported problems. 
Information about recruitment was not often
provided, but of those that did provide information,
a trial recruiting in hospital in the early
rehabilitation period had relatively low numbers of
refusal to participate (e.g. Kwakkel53 had four out
of 101 people who did not give consent), while a
trial recruiting in the community after rehabilitation
had high numbers of refusal of the intervention
(e.g. Salbach51 had 73% refusal). It may be that
some forms of intervention are less acceptable, or
that interventions only appeal to a subset of stroke
survivors, particularly if travel is involved. 
No conclusions could be reached about the impact
of numbers of repetitions as a measure of the
intensity of practice, as this information was only
provided in one or two trials. The amount of task
practice is therefore a measure of the duration (i.e.
time spent). 
By virtue of its focus on functional movement, this
review does not consider the evidence for
electronic forms of delivery of repetitive
movement such as robotics or computer-mediated
practice. The authors were also unable to
comment on the implications of different sites of
treatment, therapist-delivered versus self-delivered
interventions or group versus individual delivery,
as there were too few trials for comparison.
However, the presence of two trials involving self-
delivery in the home environment and four trials
involving group delivery of task-specific training
suggests that these modes of delivery are feasible,
and further ongoing trials should provide more
information. The studies that collected
information showed generally high levels of
satisfaction with the programme. Attendance levels
at community programmes were also very good,
suggesting that training programmes were well
received by those who chose to participate. 
Quality of evidence
For lower limb trials, Salbach and colleagues51
estimate that a sample size of 60 would be
required to detect a group difference of 28 m in
average change in the 6WMT (type I error = 0.05,
type II error = 0.10, expected dropout rate of
10%) based on the results of a pilot study67 which
recruited 91 patients. Five of the 17 trials of lower
limb interventions had sample sizes above 60 (four
RTT, one TM). For upper limb trials, the same
research group estimated that a sample size of 60
participants was required to detect a clinically
meaningful difference for the BBT.52 Of the 19
trials of upper limb interventions, five trials had
sample sizes greater than 60 (five RTT). No CIMT
trial had more than 25 participants.
Two-thirds of RTT trials had adequate allocation
concealment and most of the trials stated that
blinded independent assessors were used. Therapy
time was non-equivalent in two trials. For TM, 
two out of five trials with data included in the
meta-analysis described adequate allocation
concealment methods, blinding of outcome
assessors was attempted in three trials, and all
trials provided equivalent therapy time to
experimental and comparison groups. Only four
trials (two RTT, one CIMT, one TM) had over 20%
dropout. For CIMT, three trials provided data
unsuitable for pooling; and all of the CIMT trials
had unclear allocation concealment. 
The overall quality of the included trials provides
a degree of confidence in the pooled results for
RTT and TM, although there were only five TM
trials with data suitable for pooling from 199
participants. The results for CIMT have to be
considered in the light of small size of the trials,
together with the confounding effects of the
selection of trials with non-equivalent therapy time
in the experimental and control groups (i.e. no-
treatment control groups). A number of CIMT
trials did include comparison groups who received
therapy with no constraint, but these were
intervention–control pairs that could not be used
for this review as the comparison was also
repetitive task practice. The use of no-treatment
control comparison may lead to a different
conclusion from other reviews of CIMT. Three out
of eight included CIMT trials compared the
intervention against no therapy. This may explain
the large effect of the intervention on upper limb
function, as the differential between these groups
may be larger than would be expected by
comparing the intervention against usual care or
another intervention, such as bimanual training. 
Non-reporting bias also has to be considered.
Subgroup analysis for trial size and the funnel plot
for upper limb interventions suggested greater
effects for smaller trials, suggesting an absence of
small, negative trials. This might have led to small
or negative effect estimates not being included
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and, in particular, an ‘unbalancing’ due to the four
trials with large effects.
Potential limitations in the review
process
This review combined the results of trials of RTT
with results from trials of enhanced forms of RTT,
namely TM and CIMT. Care must therefore be
taken regarding attribution of pooled treatment
effects solely to the task practice component. For
this reason, both separate and pooled results are
shown. This study also generally used fixed-effect
analyses, which some might criticise owing to the
presence of some clinical heterogeneity in the
treatments and trials combined. Many of the trials
originally reported data in median and
interquartile ranges. In addition, many of the
outcomes are measured on scales that are short
and bounded, where the use of means and
standard deviations can be misleading. However,
the effect size for RFTP is greatest for walking
distance, which is a truly quantitative measure. It
is also relatively consistent across other outcomes,
including walking speed which is, like walking
distance, a continuous measure with essentially no
strict upper bound. This would tend to indicate
that the use of means and standard deviations for
short, bounded, ordinal scales has not
substantively affected the conclusions, at least for
the lower limb outcomes.
The major focus in this review was impact on task-
specific function. In practice, a large number of
studies was excluded on the basis that the
reviewers did not judge the outcomes to be
functional or the intervention to be task specific.
Studies were also included where the reviewers’
interpretation of the intervention was that
repetition of functional movement was a major
mechanism of action, even when this was not
explicitly stated by the authors (e.g. de Sèze76).
Whether balance training is truly ‘functional’ is
also a matter of interpretation, but its inclusion
was felt to be important so as not unintentionally
to exclude RFTP training for people with more
severe levels of disability, where the recovery of
balance is a prerequisite of functional activity. 
As CIMT and TM trials were sourced from
existing reviews, trials with alternative or 
no-treatment comparisons were included. Two TM
trials included comparisons against alternative
forms of treatment, which is potentially likely to
have resulted in lower estimates of effect than
comparison against usual care; subgroup analysis
for type of comparison group was close to
statistical significance, with a lower effect estimate
for the usual care/alternative treatment than for
the attention-control/no-treatment comparison
subgroup. Three CIMT trials included comparison
against a no-treatment group, with the potential to
result in greater estimates of effect than
comparison against usual care. However, analysis
of the impact of comparison group provided no
evidence of any difference between the effects in
the two subgroups.
Agreement or disagreement with
previous reviews
All of the studies included in this review have a
core component of repeated, task-specific practice,
but they are also very diverse. The CIMT and TM
components of the review were subsets of existing
reviews.20,23 While combining the results from such
a diverse group of studies has potential dangers,
the summary finding of a pooled moderate impact
on functional ability (SMD 0.34, 95% CI 0.19 to
0.48) supports previous authors who have
suggested a focus on the efficacy of task-specific
treatments.14,34
Whether functional gain can be attributed to task
specificity or repeated practice is unclear and any
attribution is highly speculative. This review did
not find a significant difference in treatment effect
dependent on the amount of practice for lower
limb interventions. Conversely, the greatest gains
for lower limbs were seen in walking distance,
while gains for walking speed were of a smaller
magnitude, suggesting that an endurance training
element contained in repeated motor practice
makes some contribution to impact. In addition,
this review could not take into account the
pretherapy ability levels of the participants, and it
may also be that the mechanisms of repetition and
task specificity have different roles at different
stages of recovery. Repetition is the major
mechanism of action of robotics, and a recent
review has shown impact at the level of
impairment, but not for functional ability.36
For upper limb interventions, five out of eight
CIMT studies with data suitable for pooling
provided more than 20 hours of therapy. Although
the overall difference between smaller and larger
amounts of task practice was not statistically
significant, there was potential evidence of a trend
(p = 0.18) towards larger effect sizes for more than
20 hours’ practice (SMD 0.42, 95% CI 0.10 to
0.75) versus 0–20 hours’ practice (SMD 0.22, 
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95% CI –0.12 to 0.57) for arm function. This
finding is consistent with other reviews that have
suggested that upper limb recovery may require
intensive intervention.16
Overall for RFTP, there were small to moderate
effects for ADLs and global motor function, and a
small effect on functional ambulation classification.
Even though the amount of change for these
outcomes is modest, the clinical benefits are likely
to be meaningful in relation to quality of life.136
In those studies that did show a benefit and
provided later assessments, improvements at the
end of training were not evident at the later stage.
It is unclear from this review whether this is
related to characteristics of the participants, the
intensity of training or the degree of improvement
required before detectable change was noted. 
Evidence from RFTP interventions does not
concur with the suggestion that earlier provision
of treatment results in greater functional
improvement, as treatment effects were not
modified by time since stroke. Improvement in
function was possible even in the later stages of
recovery.139 A recent review concluded that it was
surprising that CIMT should work in the chronic
phase of stroke, but agreed that the trial and
laboratory evidence suggested that this was the
case. However, they concluded that teaching
bimanual activities rather than constraint might
create the same outcome.140
The authors were unable to come to any
conclusions about the previously identified
dose–response relationship between amount of
therapy and improved outcome,15 but the results
from subgroup analysis suggest this as a priority
for further research.
Economic analysis
The base-case analysis suggested that RFTP is
cost-effective. This analysis is based on a number
of assumptions about therapeutic inputs that had
to be made because of the paucity of economic
data associated with the individual trials.
Furthermore, in calculating cost-effectiveness the
authors had to estimate the potential impact of
RFTP on pre-existing longitudinal data. To allow
for these assumptions their magnitude was varied
in sensitivity analysis. The sensitivity analyses
tended to find that RFTP was cost-effective
overall, and in particular on the outcome
measures of walking distance and sit-to-stand.
The existing data set used to estimate the impact
of RFTP was appropriate to the study’s needs
because it reflected the normal course of recovery
after stroke in a cohort of patients that had been
systematically identified. The disadvantage of
using this data set was that the analysis was based
around predetermined data, which did not
specifically lend itself to assessing the impact of
RFTP. However, the existing data did allow
reasonable assumptions to be made about how
RFTP may have affected outcomes and costs, and
meant that the research team did not have to wait
for 3 years to collect data on resource use and
outcomes in a UK post-stroke population.
One of the costs from the existing data set that
could have been included was the cost incurred
through residence in institutions. These costs tend
to be high and would most likely be important in
patients with more severe disability. Not including
the cost of residence in institutions means that the
costs of these severe states are likely to have been
underestimated. Evidence from this review
suggested that RFTP reduced disability. Therefore,
by excluding the high severe state costs due to
institutionalisation, the review is likely to have
underestimated the potential savings and
consequently the cost-effectiveness of RFTP.
Translation of the potential effect of RFTP on the
patients in the data set made an assumption about
the relationship between the effect size and the BI.
This assumption was based around the size of the
standard deviation in rehabilitation trials. The
assumption that the standard deviation was about
5 is consistent with published data.53,68,141–143
Furthermore, in this systematic review the effect of
RFTP on ADLs resulted in an SMD of 0.30. This
would suggest that the assumption about the
relationship between the SMD and the BI was, if
anything, a conservative one, therefore, it is likely
that the cost-effectiveness of RFTP has been
underestimated.
A further assumption was then made about the
relationship between the BI and the EQ-5D. This
assumption allowed the calculation of ICER per
QALY gained. The systematic review showed that
none of the studies used the EQ-5D and only one65
used a measure of quality of life (not including
health status) as an outcome. It therefore seemed
unreasonable to generate an effect size for quality
of life, based on one study. Consequently, this
makes it difficult to compare directly the
relationship between RFTP and quality of life, and
suggests that future RFTP studies should use a
quality of life measure as an outcome.
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To test the assumptions that were made about the
relationships between the effect size, the BI and
QALYs, sensitivity analyses were performed. These
analyses explored what would happen if the
impact of RFTP on outcome was less than in the
base model. For the assumptions made, the cost
per QALY gained was more sensitive to variations
between the effect size and the BI than to
variations between the BI and the EQ-5D. Overall,
the cost per QALY gained for walking distance did
not rise much above £20,000, except for one of
the assumptions made in the sensitivity analysis.
This means that even when the assumptions are
stacked against RFTP, this intervention still
demonstrates cost-effectiveness.
The estimation of the cost of providing RFTP in
the trials was complicated for a number of reasons.
Many of the trials were not conducted in the UK,
so it was difficult to cost some items of equipment.
The grade of staff performing the training was not
often reported; this was further compounded by
the trials not being UK based. In addition,
because the individual trials had not specifically
recorded resource-use data, no information was
available about the impact of RFTP on future
therapy, support services or provision of mobility
aids. Moreover, there were no consistent data
about adverse events, which would have the
potential to increase costs through patients
attending clinics or being admitted to hospital. In
one study87 some patients were transported to
hospital at the expense of the researcher; for all
other studies post discharge, patients made their
own way to clinics. It is likely that this cost was
incurred because the intervention was being used
in the context of a research study rather than
normal clinical practice. Furthermore, if RFTP was
introduced as a rehabilitation therapy it is unlikely
that it would incur major direct costs for patient
transport. For this reason the cost of this transport
was not included as a source of cost for RFTP.
Given the lack of associated economic data, the
costing of RFTP was a fair reflection of the direct
costs incurred by this intervention.
The systematic review revealed the complex nature
of RFTP in terms of what is being delivered as well
as when (after stroke), where and how it is
delivered. This provided a challenge for
modelling the cost-effectiveness of this
intervention. It was therefore decided that rather
than develop a complex model, the modelling
should be kept simple and transparent. As a result
of this decision the reviewers considered how
RFTP might influence 3-year costs by looking at
the potential impact on the 3-year BI. It is self-
evident that to have a 3-year BI a patient must be
alive; this meant that the estimate did not take
into account the possibility that a patient who had
RFTP died within the 3-year period, which may
have impacted on the cost. A further analysis was
subsequently performed that examined how the
impact of RFTP on the 3-month BI would affect
cost at 3 years, i.e. this analysis included people
alive at 3 months, some of whom had died by
3 years. It was found that the magnitude of the
potential cost saving was similar whether the 
3-month or 3-year BI scores were used.
To make the modelling feasible a number of other
assumptions had to be made. The costing of usual
care went from discharge to 3 years post-stroke,
which makes the assumption that the cost over
3 years would be the same whenever RFTP was
started. Another related assumption was that the
effect of RFTP is constant over time. It is
acknowledged that these assumptions are rather
general. However, given the complex nature of the
intervention, described in the previous paragraph,
and the lack of economic data about the
intervention and its likely impact on cost, the
authors believe that these assumptions provided a
reasonable estimate.
In summary, the systematic review was able to
combine the results from different studies and
provide an overall effect size for RFTP. The lack of
economic data associated with the existing studies
meant that an economic model had to be
developed to estimate the potential cost-
effectiveness of RFTP. The modelling had the
advantage of using effect sizes from a large
sample; the disadvantage was that it relied on pre-
existing data. This meant that the modelling that
was performed relied on a number of assumptions
about costs and effectiveness. The assumptions
that were made were generally weighted against
RFTP. Despite these assumptions, RFTP
demonstrated that it was cost-effective.
To combat the issues around measures of costs and
effectiveness, future trials need to be sufficiently
powered to detect the effectiveness of both
functional and economic outcomes. Furthermore,
trials need to decide a priori what resources to
cost; because the effects of RFTP are likely to
extend beyond its impact on direct costs future
trials should also consider indirect and possibly
intangible costs. Economic analysis would be
facilitated further by including quality of life as an
outcome measure.
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Implications for practice
The results of this review provide sufficient
evidence to validate the general principle that
RFTP for lower limbs can result in functional gain,
when compared against other forms of usual care
or attention-control. While functional gain overall
is modest, impact does appear to be of a clinically
meaningful magnitude. It is, however, unclear as
to whether effects are sustained over 6 months
post-therapy. 
There is insufficient evidence to make any
recommendations for upper limb interventions.
Although effects of RFTP on arm function were
statistically significant, the variable quality of the
evidence and the clinical heterogeneity of the
interventions mean that further research is needed
before specific recommendations can be made.
Some caution is needed in interpreting the lack of
evidence for adverse effects, as few trials
specifically monitored these as an outcome. If
task-specific training is used in clinical practice,
adverse effects should be monitored. 
While the overall effectiveness of RFTP is
relatively modest, this sort of intervention appears
to be cost-effective, primarily because the
intervention itself has a relatively small cost. 
Recommendations for future
research
There is a large number of ongoing trials in this
area. The first recommendation is that this review is
updated within 2 years. The updated review should
also consider any potential interaction effects
between type of training, amount of task practice
and stroke-related impairments. This review
focused initially on the evidence for the efficacy of
RFTP versus usual care or attention-control
comparisons. Any future review should include
comparison of RFTP against alternative forms of
therapy, such as strength and stamina training.
Further well-designed, adequately powered trials
evaluating the impact of upper limb interventions,
and in particular CIMT, are needed. One trial was
published shortly after the closing date for this
review, and should provide more information on
efficacy. Future CIMT trials should also target and
measure hand function.
There were insufficient trials included in this
review to evaluate the efficacy and cost-
effectiveness of different intervention delivery
methods for RFTP, such as group training, delivery
by assistants or practice in the home environment.
Further research should address practical and cost-
effective ways of delivering such interventions. In
particular, the acceptability of CIMT and of circuit-
training-type interventions delivered in community
settings would need to be evaluated.
The existence of retention effects up to 6 months
post-therapy is a promising finding, and further
research should be directed towards evaluating
long-term functional gain by routine inclusion of
longer follow-up periods of 1 or possibly 2 years.
Suitable methods to maintain functional gain
should also be investigated. 
Future trials need to be designed to take account
of the following:
● This study was unable to investigate the impact
of training on people with different levels of 
pre-intervention disability, because of the wide
range of baseline measures used. Analyses of this
type would be facilitated by the inclusion in trials
of baseline data using a common measure such
as the BI, which can be related to population
norms dependent on time since stroke.
● Monitoring and reporting of adverse effects
should be explicitly included.
● When designing future trials of any type of
RFTP it is critical that the study is powered to
detect not only a clinical effect, but also whether
it is cost-effective.
● Future studies need to identify clearly which
resources are likely to be affected by RFTP and
ensure that they are included in any economic
analysis. In addition, studies should include a
quality of life measure as one of the outcomes
to facilitate economic analysis.
● The benefit of RFTP may not be clear from
direct costs alone; therefore, future studies
should include indirect costs and give some
consideration to the inclusion of intangible 
costs.
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Chapter 7
Conclusions
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Included studies: repetitive task training
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Appendix 2
Included studies: constraint-induced 
movement therapy
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Included studies: treadmill training
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Appendix 4
Characteristics of excluded studies
Study Comment
RTT
Bagley, 2005145 x
Brown, 2002146 x
Carey, 2002147 x
Chan, 2006148 x
Chang, 2000149 x
Cirstea, 2003150 x
Desrosiers, 2005151 x
Duncan, 2003152 x
Eng, 2003153 x
Feys, 1998154 x
Gelber, 1995155 x
Hanlon, 1996156 x No baseline measures for function
Husemann, 2004157 x
Inaba, 1973158 x
Katz-Leurer, 2006159 x
Kayhan, 1996160 x Unable to contact author
Khanna, 2003161 x Study did not start
Kilbreath, 1997162 x Study information not available
Krutulyte, 2004163 x Unable to determine whether randomised
Li, 2005164 x
Liao, 2006165 x
Mudie, 2002166 x
Nelles, 2001167 x Not designed to evaluate intervention
Pang, 2006168 x
Platz, 2001169 x No subgroup data
Pollock, 2002170 x
Sunderland, 1992171 x
Theilman, 2004172 x
Wellmon, 1997173 x
Xiao, 2002174 x
Yang, 2005175 x
CIMT
Ploughman, 2004176 x
Ro, 2006177 x Subgroup of Boake, 200684
Sterr, 2002178 x Not RCT
Van der Lee, 1999179 x
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Study Comment
TM
Jaffe, 2004180 x
Kosak, 2000181 x
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Appendix 5
Characteristics of ongoing studies
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Appendix 6
Criteria for subgroup analyses
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Appendix 7
Summary of baseline characteristics of patients 
from the cohort in the patient data set who 
survived to 3 years
Age (years) median (IQR) 69.5 (64 to 77)
Gender female, n (%) 58 (39)
Lesion type, n (%)
IC 108 (72)
Primary intracerebral haemorrhage 17 (11)
Haemorrhagic transformation of IC 4 (3)
No scan 21 (14)
Side, n (%)
Left 52 (35)
Right 64 (42)
No bilateral signs 34 (23)
IC, ischaemic infarction.
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Appendix 8
Numbers of patients and costs in the 
baseline and new groups
Baseline groups New groups
Barthel category Average cost n Total cost na Total cost Difference
10 £4,398 28 £123,154 25.5 £111,958
11–14 £6,874 34 £233,727 28.0 £192,793
15–17 £4,914 33 £162,169 30.5 £149,883
18 or 19 £2,153 25 £53,819 23.5 £50,589
20 £1,610 30 £48,291 42.5 £68,412
Total 150 £621,159 150 £573,636 £47,523
Average £4,141 £3,824 £317
a Approximate.
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Appendix 9
Cost-effectiveness at 3 years per QALY gained 
for RFTP on outcome measures that 
were significant in the systematic review
Analysisa Outcome Overallb Arm ADLc Walking Functional Sit-to-
functionc distanced ambulationd standd
1 SMD £10,870 £15,185 £11,009 £4,187 £10,187 £5,708
SMD lower limit CI £23,947 £77,821 £49,983 £16,539 £83,239 £19,010
SMD upper limit CI £6,039 £6,237 £3,942 £658 £3,025 £1,596
2 SMD: BI; 0.2:1.0 £10,870 £15,185 £11,009 £4,187 £10,187 £5,708
SMD: BI; 0.2:0.8 £15,011 £20,405 £15,185 £6,658 £14,157 £8,558
SMD: BI; 0.2:0.6 £21,913 £29,104 £22,144 £10,775 £20,774 £13,309
SMD: BI; 0.2:0.4 £35,716 £46,503 £36,064 £19,010 £34,008 £22,810
SMD: BI; 0.2:0.2 £77,126 £98,700 £77,821 £43,713 £73,711 £51,315
3 BI: EQ-5D; 1:0.05 £10,870 £15,185 £11,009 £4,187 £10,187 £5,708
BI: EQ-5D; 1:0.04 £13,587 £18,981 £13,761 £5,234 £12,734 £7,135
BI: EQ-5D; 1:0.03 £18,116 £25,308 £18,348 £6,979 £16,978 £9,513
BI: EQ-5D; 1:0.02 £27,175 £37,962 £27,523 £10,469 £25,467 £14,269
BI: EQ-5D; 1:0.01 £54,349 £75,924 £55,045 £20,937 £50,935 £28,538
4 £35 per hour £9,143 £12,712 £9,031 £3,283 £8,734 £4,664
£40 per hour £10,870 £15,185 £11,009 £4,187 £10,187 £5,708
£45 per hour £12,597 £17,657 £12,987 £5,092 £11,640 £6,751
£50 per hour £14,323 £20,129 £14,965 £5,996 £13,093 £7,794
£55 per hour £16,050 £22,602 £16,943 £6,900 £14,546 £8,837
£60 per hour £17,777 £25,074 £18,921 £7,804 £15,999 £9,880
5 Discount = 0% £10,228 £14,543 £10,367 £3,545 £9,545 £5,065
Discount = 3.5% £10,870 £15,185 £11,009 £4,187 £10,187 £5,708
Discount = 6.0% £11,301 £15,616 £11,440 £4,619 £10,618 £6,139
6 Discount = 0% £9,191 £13,068 £9,316 £3,186 £8,577 £4,552
Discount = 3.5% £10,870 £15,185 £11,009 £4,187 £10,187 £5,708
Discount = 6.0% £12,227 £16,895 £12,377 £4,997 £11,488 £6,642
a 1, Base case; 2, varying the association between the SMD and the BI (shaded cells are base case); 3, varying the association
between the BI and the EQ-5D (shaded cells are base case); 4, varying the cost per hour of client contact with therapist
(shaded cells are base case); 5, varying the discount rate on cost (shaded cells are base case); 6, varying the discount rate
on outcome (shaded cells are base case).
b Cost per QALY gained, where the cost of the intervention is £1265 (based on the average cost of RTT, CIMT and TM).
c Cost per QALY gained, where the cost of the intervention is £1126 (based on the average cost of RTT and CIMT).
d Cost per QALY gained, where the cost of the intervention is £999 (based on the average cost of RTT and TM).
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